HOME -
Today, society faces many challenges. Too many people suffer from diseases that are not diagnosed accurately, not well treated, not cured satisfact...Read more
TRACK RECORD -
Over the past 30 years, we have provided start-up and growth capital to more than 200 companies. Operating at the forefront of medical innovation, ...Read more
TEAM -
Our successful 30 year investment history is based on our conviction that seeking, helping and supporting the smartest people with the best ideas r...Read more
FUNDS -
Our activities as a dedicated private equity healthcare investor date back to the late 1980s. At that time, providing start-up and growth capital t...Read more
PORTFOLIO -
Our activities as a dedicated private equity healthcare investor date back to the late 1980s. At that time, providing start-up and growth capital t...Read more
IMPACT -
The companies we invest in all help to address some of the medical needs that are not met by current products or technologies. In other words, they...Read more
Translating academic careers into industry healthcare professions -
Though academic institutions have contributed enormously to the remarkable gr...Read more
GTX medical Granted FDA Breakthrough Device Designation for Go-2 Targeted Epidural Spinal Stimulation (TESS) System -
Eindhoven, NL and Lausanne, CH: June 9, 2020 - GTX medical (GTX), today annou...Read more
argenx announces positive topline Phase 3 ADAPT Trial Results -
May 26, 2020 - Breda, the Netherlands / Ghent, Belgium
Trial ...Read more
argenx announces full exercise of underwriters’ option to purchase additional ADSs -
May 29, 2020 - Breda, the Netherlands / Ghent, Belgium - argenx (Euro...Read more
Zealand Pharma announces FDA acceptance of New Drug Application for the dasiglucagon HypoPal® rescue pen for treatment of severe hypoglycemia -
The dasiglucagon HypoPal® rescue pen New Drug Application represents a m...Read more
LSP portfolio company Orphazyme announced that the company has received Fast Track Designation from FDA -
Orphazyme’s arimoclomol receives US Fast Track Designation in Amyotrophic L...Read more
First truly biocompatible MIGS implant from iSTAR Medical shows consistently outstanding efficacy in patients with glaucoma -
Two-year final results from STAR-I trial and initial data from STAR-II Europe...Read more
Immunic, Inc. Announces Pricing of $15 Million Financing -
NEW YORK, April 23, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a c...Read more
Immunic Inc. has demonstrated preclinical activity against SARS-CoV2 -
NEW YORK, April 21, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a c...Read more
FoRx Therapeutics AG Raises EUR 10 Million Seed Round -
First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress...Read more
COVID-19 – Perspective from a Biotech Investor Part 2 -
by Geraldine O'Keeffe and Mark Wegter
Amsterdam, April 23, 202...Read more
Binx aims to capture a milestone in STI testing technology -
Three months ago Binx Health, a Boston-based biotech firm founded in 2005, st...Read more
Simplify Medical Completes PMA Submission for 1-Level Simplify Disc IDE Study -
SUNNYVALE, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Simplify Medical Pty Lt...Read more
AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI -
€23m (US$25.5m) equity provided mainly by US-based Cowen Healthcare Inv...Read more
Zealand Pharma submits New Drug Application -
Zealand Pharma submits New Drug Application to the U.S. Food and Drug Adminis...Read more
COVID-19 – Perspective from a Biotech Investor -
by Geraldine O’Keeffe and Mark Wegter
The purpose of this memo i...Read more
LSP’s portfolio company eTheRNA launches SARS-CoV-2 mRNA vaccine program for COVID-19 -
eTheRNA Launches an International Consortium and Starts Development of Cross-...Read more
LSP closes largest ever European life sciences fund at $600 million -
Amsterdam, Munich, Boston, 10 March 2020
LSP, the leading life s...Read more
Orphazyme completes offering of 7,032,937 shares in a directed issue and private placement -
Copenhagen, Denmark, February 7, 2020 – Orphazyme A/S (ORPHA.CO), a biophar...Read more
Atlantic Therapeutics Announces FDA Clearance for Over-the-Counter Use of INNOVO -
February 06, 2020
GALWAY, Ireland--Atlantic Therapeutics, a global...Read more
LSP portfolio company binx announces launch of its pre-order program for the world's first FDA-cleared, rapid molecular point-of-care instrument -
binx offers first FDA 510(k) cleared molecular point-of-care solution for tes...Read more
LSP 5 portfolio company ImCheck Therapeutics raises € 48 million ($ 53 million) to drive clinical program for cancer and autoimmune diseases -
Amsterdam, The Netherlands, December 04, 2019 – LSP, the leading European l...Read more
LSP's portfolio company Arvelle announces FDA approval of anti-epileptic drug cenobamate -
Amsterdam, 26 November 2019 - LSP's portfolio company Arvelle Therapeutic...Read more
LSP’s portfolio company GTX medical and NeuroRecovery Technologies Inc. merge to create leading neurostimulation company for spinal cord injury -
Eindhoven, NL and Lausanne, CH; Los Angeles, USA; October 22, 2019 – GTX m...Read more
LSP’s portfolio company GTX medical and NeuroRecovery Technologies Inc. merge to create leading neurostimulation company for spinal cord injury -
Eindhoven, NL and Lausanne, CH; Los Angeles, USA; October 22, 2019 – GTX m...Read more
Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions -
Tumor shrinkage observed in three patients harboring NRG1 fusions (two pancre...Read more
LSP portfolio company ARGENX successfully raises $484 million in a public offering -
LSP portfolio company ARGENX successfully raises $484 million in a public off...Read more
LSP portfolio company Merus successfully raises $68.9 million in a public offering -
LSP portfolio company Merus successfully raises $68.9 million in a public off...Read more
SCOPE 'Dossier Private equity' -
In de bijzondere seminareditie van Mgmt. SCOPE 'Dossier Private equity...Read more
Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist -
SAN DIEGO, Sept. 18, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a cli...Read more
LSP portfolio company Pharvaris B.V. announced a $66 mln Series B round -
Pharvaris Announces $66 Million Series B Financing to Advance the Clinical De...Read more
Immunic, Inc.'s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range -
– Unblinded Data Review Committee Recommended Continuation of the Lowes...Read more
LSP joins as new investor in Nkarta Therapeutics in it's series B finanancing -
Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Mult...Read more
LSP leads EUR 40 million Series C funding in iSTAR Medical -
Amsterdam, the Netherlands — 5 September 2019: LSP, one of Europe’s leadi...Read more
Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusion -
Kuros to conduct Phase 2a trial in spinal fusion, comparing Fibrin-PTH to...Read more
LSP portfolio company Binx Health to receive 510(k) marketing authorization for its io- system -
binx io enables first-ever “test-and-treat” paradigm with sample to answe...Read more
Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Primary Sclerosing Cholangitis -
– Study Being Conducted in Collaboration with Investigators at Arizona Stat...Read more
Immunic AG Awarded Research Grant by German Federal Ministry of Education and Research in Support of the InnoMuNiCH Project -
SAN DIEGO, Aug. 1, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clini...Read more
ImCheck Therapeutics Awarded €2 Million from Bpifrance to Advance its First-in-Class Immunotherapy Program into the Clinic -
Bpifrance views ImCheck’s projects as unique and well-positioned
Mar...Read more
LSP leads €67m [$75m] Series A financing in Alizé Pharma 3 -
Significantly oversubscribed financing round with an LSP-led internationa...Read more
Imcyse gives hope to patients with diabetes and MS -
De Tijd - Biotech bedrijf Imcyse biedt hoop aan patiënten met diabetes en MS...Read more
Curetis Files for U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens -
Final LRT BAL panel demonstrates overall weighted average sensitivity of ...Read more
Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC) -
US Food and Drug Administration (FDA) agrees to Orphazyme’s plan to fi...Read more
ImCheck Therapeutics appoints Paul Frohna MD, PhD, PharmD, as Chief Medical Officer -
Paul Frohna brings over 15 years of experience in translational medicine and ...Read more
Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in Amyotrophic Lateral Sclerosis -
Headline results from full analysis expected in H1 2021
Cope...Read more
Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer -
SAN DIEGO, July 16, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clin...Read more
LSP in the FD – ‘Biotechbedrijf AM Pharma haalt €116 mln op’ -
Today in the Financieele Dagblad 'Biotech company AM Pharma raising €11...Read more
LSP leads €116m [$133m] financing in AM-Pharma to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury -
Financing led by LSP and co-led by Andera Partners, with participation of...Read more
MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology -
HALLE (SAALE) and PLANEGG/MUNICH, Germany, 8 July 2019: Vivoryon Therapeutics...Read more
Immunic, Inc. to Present Previously Unpublished Data Regarding Lead Program, IMU-838, at the GI Inflammatory Diseases Summit in Boston -
SAN DIEGO, June 24, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clin...Read more
LSP's portfolio company Nouscom demonstrates Preclinical Proof of Concept for Personalized Cancer Neoantigen Vaccine in combination with Immune Checkpoint Blockade to Eradicate Large Tumors -
Article published in Nature Communications
BASEL, Switzerland – 19...Read more
LSP leads € 28 million Series B financing in Imcyse -
Imcyse raises a total of € 35 million in equity and grants and will use pro...Read more
Merus Announces Financial Results for the First Quarter 2019 and Provides Business Update -
UTRECHT, The Netherlands, May 30, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq...Read more
argenx announces publication of efgartigimod Phase 2 myasthenia gravis trial results in Neurology -
Breda, the Netherlands / Ghent, Belgium, May 28, 2019 – argenx (Euronext &...Read more
Kiadis Submits Response to the European Medicines Agency's Day 180 Second List of Outstanding Issues -
Amsterdam, The Netherlands, May 22, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma...Read more
argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day -
Expands pipeline with ARGX-117 and ARGX-118; two new pipeline candidates ...Read more
LSP leads $38.5 Million Series B Financing in DNA Script -
Oversubscribed round led by LSP will fund accelerated product development and...Read more
Okairos winner of the Swiss Biotech Success Stories Awards 2018/19 -
Basel, Switzerland, May 7, 2019 – LSP is pleased to announce that Okairos h...Read more
Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors -
UTRECHT, Netherlands, May 09, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq...Read more
argenx reports first quarter 2019 financial results and provide business update -
Breda, the Netherlands / Ghent, Belgium, May 9, 2019 - argenx (Euronext & Na...Read more
LSP’s portfolio company Binx Health Receives CE Mark for Rapid Chlamydia and Gonorrhea Test for Mass Markets -
Multiplex Test Panel for binx io® Point-of-Care Platform
Positioned to R...Read more
Immunic, Inc. Appoints Industry Veteran Tamara A. Seymour as Interim Chief Financial Officer -
SAN DIEGO, April 29, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage ...Read more
The French Région Sud and the European Union provide grant funding to Imcheck Therapeutics and its development of a new generation of cancer treatments -
Through a 717 K€ grant co-financed by the Région Sud and the European Unio...Read more
LSP Life Sciences Fund Performing strongly and ending Q1 2019 up +17.5% -
For more insight into our returns and investment strategy please read our jus...Read more
Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases -
Developing Oral Therapies with Best-in-Class Potential
Lead Program...Read more
Upcoming Event: Biotech update 2019 -
Biotech Update 2019
Wednesday 26th June, 2019
Kasteel De Wittenburg i...Read more
Probiodrug raises EUR 8.2 million from investors in successful private placement of new shares -
Capital increase of its share capital by issuing 4,093,367 new shares at ...Read more
Merus Announces Financial Results for the Full Year 2018 and Provides Business Update -
Multiple Updates from Biclonics® Clinical Trials Expected in 2019
...Read more
Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019 -
CD137 and PD-L1 bispecific antibody with context-dependent T cell activation
...Read more
Curetis and Menarini Diagnostics Enter into Strategic Pan-European Exclusive Partnership for the Distribution of Curetis’ Unyvero -
Curetis and Menarini Diagnostics Enter into Strategic Pan-European Exclusive ...Read more
Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases -
Collaboration furthers Alexion’s complement leadership with expansion i...Read more
Probiodrug and Alzheimer’s Disease Cooperative Study (ADCS) Receive 15 Million USD National Institutes of Health (NIH) Grant for U.S. Phase 2b Core Program for PQ912 -
HALLE (SAALE), Germany and San Diego, CA – USA, 20 March 2019 – Probiodru...Read more
EMA making its first public appearance at our conference -
The timing was perfect – the EMA would complete its move to Amsterdam in Ma...Read more
Amarin – a story close to our hearts, Keynote speaker at BioCapital -
Keynote speaker CEO John Thero telling this remarkable story on our BioCapita...Read more
argenx to receive first clinical milestone payment for product candidate developed under option agreement with AbbVie -
Initiation of first-in-human clinical trial with antibody product candida...Read more
LSP co-leads $50 million Series A financing in SNIPR BIOME -
Copenhagen, 11 March 2019 - SNIPR BIOME, a leading CRISPR and microbiome priv...Read more
argenx reports fourth quarter business update and full year 2018 financial results -
Breda, the Netherlands / Ghent, Belgium - February 28, 2019 – argenx (Euron...Read more
Immunic Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of IMU-838, an Oral Therapy for Patients with Relapsing-Remitting Multiple Sclerosis -
Planegg-Martinsried, Germany, February 26, 2019 – Immunic AG (Immunic), a p...Read more
LSP leads $180 million Series A Financing in Newly-Formed Arvelle Therapeutics -
LSP leads one of the largest initial financings for a European biotech compan...Read more
Kuros Biosciences signs agreement to supply SeaSpine with bone graft incorporating Kuros’s advanced submicron surface technology -
Global partner to market an advanced bone graft supplied by Kuros
A...Read more
LSP's portfolio company GTX Medical on “Dokters van Morgen” -
Dutch TV program 'Dokters van Morgen' reporting on new revolutionary ...Read more
argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology -
argenx gains access to ENHANZE® subcutaneous delivery technology for up ...Read more
Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC) -
Primary endpoint shows 74% reduction in disease progression after 12 mont...Read more
LSP leads €28 million Series B financing in Atlantic Therapeutics -
Amsterdam, the Netherlands, January 7, 2019 – LSP, one of Europe’s leadin...Read more
Merus Announces IND Clearance for MCLA-145 -
MCLA-145 is a full-length human bispecific antibody binding to PD-L1 and CD13...Read more
Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company -
Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Fo...Read more
Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Update -
Clinical milestones for four lead Biclonics® programs expected in 2019
C...Read more
Merus Announces Strategic Collaboration with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China -
Merus to retain all global rights outside of China
Betta Pharmaceuticals ...Read more
Merus Announces Global Settlement and End to All Patent Litigation with Regeneron Pharmaceuticals -
Merus and Regeneron to cross-license patents relating to certain antibody gen...Read more
Kuros ends transformational year with first MagnetOs sales, lead clinical program on track, and successful capital raise -
Successfully raised CHF 16.1 million from existing and new investors
...Read more
Kuros announces final result of capital increase – total gross proceeds of 16.1 million raised -
Schlieren (Zurich), Switzerland, December 13, 2018 – Kuros Biosciences (SIX...Read more
Kuros announces results of rights offering – capital increase will be implemented -
Schlieren (Zurich), Switzerland, December 12, 2018 – Kuros Biosciences (SIX...Read more
Aelin Therapeutics pursues new cancer drugs -
The young biotech spin-off gains momentum with a VLAIO grant and an investor ...Read more
Orphazyme expects to announce results of full data set for Niemann-Pick disease Type C (NPC) Phase II/III trial in Q1 2019 -
Copenhagen, December 10, 2018 – Orphazyme A/S, a biopharmaceutical company ...Read more
LSP co-leads $17 Million Series A financing in XyloCor Therapeutics to advance gene therapy in cardiovascular disease -
Novel gene therapy for patients with treatment-resistant angina who have ...Read more
LSP leads $28 million financing in Lumeon -
Amsterdam, the Netherlands, December 4, 2018 – LSP, one of Europe’s l...Read more
argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia -
Detailed Phase 2 ITP data show clear correlation between IgG reduction, p...Read more
argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110) -
Regulated information – Inside information
Collaboration to de...Read more
LSP wins Lifestars Award for EU investment firm of the year -
Celebrating success across life sciences
Amsterdam, The Netherland...Read more
Simplify Medical Completes Enrollment in U.S. IDE Pivotal Trial of Simplify® Disc for Two-Level Cervical Disc Replacement -
Sunnyvale, CA – November 14, 2018 – Simplify Medical Pty Ltd., maker of t...Read more
LSP raises record €750 million in 10 months for life sciences innovations -
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JA...Read more
Immunic enters into a global option and license agreement with Daiichi Sankyo -
Immunic AG gains exclusive, worldwide rights to promising drug development pr...Read more
Product of LSP’s portfolio company GTX medical restores walking in humans with spinal cord injury -
Amsterdam, The Netherlands, November 1, 2018 – LSP’s portfolio company GT...Read more
argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exposition -
Regulated information – Inside information
92% overall response ra...Read more
argenx reports third quarter 2018 financial results and provides business update -
Breda, the Netherlands / Ghent, Belgium, October 25, 2018 - argenx (Euronext...Read more
Orphazyme reports encouraging arimoclomol clinical trial top-line data in Niemann-Pick disease Type C (NPC) -
Arimoclomol was well-tolerated in patients with the rare disease NPC
...Read more
Merus Strengthens Team with Key Appointments -
Hui Liu, Ph.D., EVP, Chief Business Officer, appointed Head of Merus U.S.
...Read more
Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children -
The pediatric Phase 3 trial will enroll up to 40 children with Type 1 dia...Read more
argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia -
Favorable safety and tolerability consistent with efgartigimod clinical t...Read more
LSP leads $45 million Series D Financing in Endotronix -
Amsterdam, the Netherlands, September 17, 2018 – LSP, Europe’s leading li...Read more
argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis -
Breda, the Netherlands / Ghent, Belgium, September 6, 2018 - argenx (Euronex...Read more
Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets -
Affimed will receive $96 million upfront and committed funding and is eligibl...Read more
Merus Announces Formation of a Scientific Advisory Board -
- Key Oncology and Drug Development Professionals to Support Advancement of M...Read more
argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody -
Breda, the Netherlands/Ghent, Belgium, August 22, 2018 - argenx (Euronext & N...Read more
LSP co-leads $85 million (£65 million) Series B Financing in Artios Pharma -
LSP returns to support the former KuDOS team that successfully developed the ...Read more
argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris -
Rapid disease control observed in 4/6 patients
Strong PD effect cor...Read more
argenx receives second preclinical milestone payment under its development agreement with AbbVie -
Breda, the Netherlands/Ghent, Belgium, June 28, 2018 - argenx (Euronext & Na...Read more
Kuros Biosciences to present promising clinical case studies with MagnetOs at leading spine surgery conference -
Schlieren (Zurich), Switzerland, June 19, 2018 - Kuros Biosciences will this ...Read more
argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation -
- Subcutaneous formulation offers potential for increased patient convenience...Read more
Zealand Pharma achieves milestone in first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes -
Zealand Pharma achieves milestone in first Phase 3 trial with dasiglucagon fo...Read more
eTheRNA enrols first patient in high dose cohort of Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma -
Niel (Belgium), 24 May 2018 — eTheRNA immunotherapies, a clinical-stage com...Read more
Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors -
- IND Accepted in April by the U.S. FDA for MCLA-158 -
UTRECHT, The Ne...Read more
Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell -
UTRECHT, The Netherlands, May 15, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Na...Read more
De Telegraaf: gespreid in biotech en profiteren van overnames via LSP -
Lees de gehele column: gespreid in biotech en profiteren van overnames via LS...Read more
argenx reports first quarter 2018 financial results and provides business update -
Breda, the Netherlands / Ghent, Belgium, May 9, 2018 - argenx (Euronext ...Read more
Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017 -
Phase 2 combination trial in two metastatic breast cancer (MBC) populatio...Read more
Immunic reports start of enrollment into clinical Phase 2 study with IMU-838 in patients with ulcerative colitis -
First patient with ulcerative colitis entered the ‘CALDOSE-1’ trial w...Read more
Probiodrug Appoints Dr. Ulrich Dauer as Chief Executive Officer -
Dr. Ulrich Dauer to team up with Chief Development Officer, Dr. Inge Lues, ef...Read more
argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting -
Eight-week follow-up data show separation of clinical efficacy scores bet...Read more
argenx to receive third preclinical milestone payment from collaboration with LEO Pharma - Milestone associated with CTA approval for ARGX-112 -
Breda, the Netherlands/Ghent, Belgium, April 12, 2018 - argenx (Euronext & Na...Read more
Zealand and Roche Diabetes Care enter Phase 3 study collaboration for treatment of congenital hyperinsulinism with dasiglucagon -
Zealand has entered a collaboration agreement with Roche Diabetes Care to...Read more
argenx appoints Keith Woods as Chief Operating Officer -
Breda, the Netherlands / Ghent, Belgium, April 9, 2018 - argenx (Euronext & ...Read more
argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe -
Breda, the Netherlands / Ghent, Belgium, March 26, 2018 - argenx (Euronext &...Read more
Merus and the Vall d’Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applications in the Treatment of Cancer -
UTRECHT, The Netherlands, March 20, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasd...Read more
Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune Diseases -
UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasd...Read more
Merus’ Intellectual Property Portfolio Expands with Two New Patents -
Merus’ First U.S. Patent Covering MCLA-117 and Merus’ Spleen to Screen® ...Read more
Merus Announces $55.8 Million Private Placement Offering of Common Stock -
UTRECHT, The Netherlands, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasda...Read more
LSP invests in Simplify Medical to bring the company’s innovative cervical disc to the US Market -
Amsterdam, the Netherlands - 12 February 2018 - LSP announces its investment ...Read more
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten -
Oncode Institute combines 600 of the very best oncology researchers with a hi...Read more
LSP Life Sciences Fund makes 250% on Ablynx sale -
To read the full article click here.
...Read more
Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations -
Combination trial to evaluate MCLA-128 in HER2-positive and hormone receptor-...Read more
Merus and Simcere Announce Strategic Collaboration on Multiple Bispecific Antibodies -
UTRECHT, Netherlands and NANJING, China, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Me...Read more
BioCapital Europe 2018, organised by LSP -
BioCapital Europe 2018, an LSP (Life Sciences Partners) event, is delighted t...Read more
LSP reaches milestone: 10 years investing in listed Life Sciences Securities -
LSP Life Sciences Fund generates net return of 39% in 2017
Amsterd...Read more
FDA approves IND for Immunic Therapeutics’ IMU-838 to proceed with Phase 2 study in ulcerative colitis -
FDA has granted IND approval for Immunic’s oral investigational drug IM...Read more
Takeda to acquire LSP portfolio company TiGenix -
Takeda announces its intention to acquire TiGenix
Leuven (BELGIUM)...Read more
Merus Provides Clinical Updates for MCLA-117 and MCLA-158 Programs -
- IND submitted to U.S. FDA for MCLA-117 in AML -
- First CTA approval fo...Read more
Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron -
UTRECHT, The Netherlands, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasda...Read more
Kiadis CEO interviewed by the Dutch financial radio station BNR -
Good afternoon, As we continue to make significant operational progress at Ki...Read more
argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering -
Regulated information - Inside information
Breda, the Netherlan...Read more
Immunic Therapeutics Successfully Completes two Phase 1 Studies for IMU-838 -
Two phase 1 studies for IMU-838 in healthy volunteers have been completed...Read more
LSP Raises EUR 280 Million to Invest In Healthcare Innovation -
Largest fund in Europe dedicated to medical technology
Significant fundra...Read more
Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH -
Completed dose-escalation shows combination of AFM13 and pembrolizumab is wel...Read more
LSP leads EUR 27 mln Series A financing of new VIB start-up Aelin Therapeutics to exploit its proprietary Pept-in™ protein knockdown platform -
Leuven, Belgium – 11 December 2017 – Aelin Therapeutics, a privately held...Read more
argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting -
Workshop to be held on Monday, December 11th at 12:00 pm EST
Breda, the ...Read more
argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis -
Favorable tolerability profile consistent with Phase 1 data
ARGX-11...Read more
LSP Partner Clemens van Blitterswijk gives a Tedx on the future of regenerative medicine -
The video is now online via the following link
...Read more
LSP's portfolio company Affimed described -
To read the full article click here.
...Read more
Is a cure for cancer finally within reach? -
To read the full article click here
...Read more
Kuros Biosciences May Secure Equity Financing of up to CHF 30 million -
Schlieren (Zurich), Switzerland, November 22, 2017 - Kuros (SIX: KURN) announ...Read more
LSP’s portfolio company Orphazyme raises approximately €80 million in oversubscribed IPO -
Amsterdam, The Netherlands – 16 November 2017 – It is with great pleasure...Read more
LSP’s portfolio company Xeltis raises a substantial new round -
Amsterdam, the Netherlands, November 16, 2017 – LSP (Life Sciences Partners...Read more
argenx launches Phase I trial with subcutaneous formulation of ARGX-113 -
Subcutaneous formulation intended for chronic therapy setting
Octo...Read more
LSP portfolio company Nouscom raises € 42m Series B round -
Financing to advance its pipeline of neoantigen cancer based immunotherapies ...Read more
argenx reports third quarter 2017 financial results and provides business update -
October 26, 2017, Breda, the Netherlands / Ghent, Belgium argenx (Euronext Br...Read more
Ventaleon GmbH reports clear clinical progress and additions to the Supervisory Board -
- Last participant enters human challenge trial, data expected by year end 20...Read more
U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome -
Copenhagen, Denmark, October 24, 2017 - The U.S. Food and Drug Administration...Read more
Smith & Nephew acquires tissue regeneration technology for shoulder repair -
Amsterdam, the Netherlands, October 24, 2017 - Smith & Nephew plc (LSE:SN, NY...Read more
LSP portfolio company Imcheck Therapeutics obtains 1M€ from Bpifrance to contribute to the development of a novel therapeutic antibody in immuno-oncology -
First non-dilutive funding received by ImCheck
following its initial fu...Read more
argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis -
Non-regulated information
Breda, the Netherlands / Ghent, Belgium,...Read more
Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress -
UTRECHT, The Netherlands, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASD...Read more
Merus’ Intellectual Property Portfolio Expands with Two New Patents For its Biclonics® Technology -
UTRECHT, The Netherlands, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Merus (NASDAQ:MR...Read more
Kiadis Pharma receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation for ATIR101™ -
Amsterdam-Duivendrecht, The Netherlands, September 20, 2017 – Kiadis Pharma...Read more
argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia -
Top-line data from the study expected in second half of 2018 -
...Read more
BioCentury: LSP's Four of a Kind -
To read the full article click here
...Read more
Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million -
Omega and Fund+ broaden Immunic’s investor base and add an additional E...Read more
Kuros receives clearance for MagnetOs Putty for commercialization in the United States and files the product for CE marking in Europe -
Schlieren (Zurich), Switzerland, August 28, 2017 – Kuros Biosciences announ...Read more
argenx reports second quarter business update and half-year 2017 financial results -
Breda, the Netherlands / Ghent, Belgium, August 24, 2017 - argenx (Euronext ...Read more
argenx announces publication in Nature Medicine of preclinical data supporting the therapeutic potential of SIMPLE AntibodyTM ARGX-116 for the treatment of dyslipidemia -
- anti-ApoC3 antibody developed as part of research collaboration with Staten...Read more
U.S. Court of Appeals for the Federal Circuit affairms Merus’ inequitable conduct claim against Regeneron -
UTRECHT, The Netherlands, July 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasda...Read more
Kiadis Pharma proposes former Actelion COO Otto Schwarz as new Supervisory Board member -
Amsterdam-Duivendrecht, The Netherlands, July 26, 2017 – Kiadis Pharma N.V....Read more
LSP extends its portfolio in medical devices and invests in Simplify Medical -
Amsterdam, the Netherlands - 20 July 2017 - LSP (Life Sciences Partners) anno...Read more
Marco Groot blikt in het FD terug op zijn eerdere positieve aanbeveling op LSP -
Lees de gehele column: Actief beleggen loont
...Read more
Merus Announces First Quarter 2017 Financial Results and Mid-Year Operating Results -
Balance sheet strengthened with $120 million upfront payment and an $80 milli...Read more
eTheRNA advances in-vivo mRNA cancer immunotherapy into first oncology clinical studies -
TriMix-MEL (ECI-003), a rationally designed mRNA immunotherapy based on the u...Read more
argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein at Best of ASCO Asia 2017 (Singapore) -
Breda, the Netherlands / Ghent, Belgium, July 7, 2017 - argenx (Euronext & Na...Read more
Zealand initiates first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes -
First patients enrolled in a multinational Phase 3 clinical trial of dasi...Read more
BioCapital Europe 2018, organised by LSP -
BioCapital Europe 2018, organised by LSP (Life Sciences Partners) is delighte...Read more
argenx receives second preclinical milestone payment in collaboration with LEO Pharma -
Breda, the Netherlands / Ghent, Belgium, June 20, 2017 - argenx (Euronext & N...Read more
Zealand Pharma announces positive results from the Phase 2 trial of glepaglutide -
Glepaglutide meets primary endpoint in Phase 2 trial in patients with short b...Read more
argenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-cell lymphomas at the International Conference of Malignant Lymphoma (ICML) -
Breda, the Netherlands / Ghent, Belgium, June 14, 2017 - argenx (Euronext & N...Read more
LSP’s portfolio company Probiodrug reports positive results in Alzheimer Disease Patients -
Munich/Amsterdam – 13 June 2017 – LSP proudly announces that its port...Read more
Ventaleon GmbH Initiates Challenge Trial with Inhaled Flu Treatment Candidate -
Human challenge study to assess safety, tolerability and efficacy of inha...Read more
Zealand Pharma announces positive Phase 2a results with microdoses of dasiglucagon support use in a dual-hormone artificial pancreas system -
Dasiglucagon is a potential first-in-class glucagon analogue for pump use...Read more
argenx announces full exercise of underwriters' option to purchase additional ADSs -
Regulated information - inside information
Breda, the Netherlands ...Read more
LSP’s portfolio company argenx raises approximately $100 million with NASDAQ IPO -
Amsterdam, The Netherlands – 19 May 2017 – It is with great pleasure that...Read more
Merus Announces Promising Results from MCLA-128 Phase 1/2 Study in Metastatic Breast Cancer -
Results to be presented at the 2017 American Society of Clinical Oncology Ann...Read more
argenx announces size of initial public offering in the United States increased to 5 million ADSs -
Regulated information - inside information
Breda, the Netherlands ...Read more
LSP leads € 15M series A round of Cardiovascular start-up Cardior Pharmaceuticals -
Munich, Germany — May 11, 2017 — LSP (Life Sciences Partners), a leading ...Read more
LSP Portfolio Company Luxendo acquired by Bruker -
Successful exit after 1,5 years validates LSPs investment rationale
...Read more
argenx announces launch of proposed initial public offering in the United States -
Regulated information - inside information
Breda, the Netherlands ...Read more
argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis -
Top-line data from the study expected in first quarter of 2018
Bred...Read more
CORRECTING and REPLACING -- Merus Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Developments -
In a release issued April 28, 2017 by Merus N.V. (Nasdaq:MRUS) with the same ...Read more
LSP extends its portfolio in immuno-oncology and invests in the € 20 million Series A round of Imcheck Therapeutics -
Amsterdam, the Netherlands — May 3, 2017 — LSP (Life Sciences Partners), ...Read more
argenx reports first quarter 2017 financial results and provides business update -
Breda, the Netherlands/Ghent, Belgium, May 2, 2017 - argenx (Euronext Bruss...Read more
Kiadis Pharma announces filing of marketing authorization with the European Medicines Agency for ATIR101™ in blood cancers -
Amsterdam, The Netherlands, April 26, 2017 – Kiadis Pharma N.V. (“Kiadis ...Read more
Recent Data on Curetis’ Unyvero ITI Application Demonstrate its Clinical and Health Economic Benefits -
Several ECCMID 2017 presentations highlight advantages of rapid time to r...Read more
argenx announces results of Annual General Meeting 2017 -
Breda, the Netherlands / Ghent, Belgium, April 26, 2017 - argenx N.V. (Eurone...Read more
argenx files registration statement for a proposed public offering in the United States -
Breda, the Netherlands / Ghent, Belgium, April 24, 2017 - argenx N.V. (Eurone...Read more
Merus Announces Data from a Phase 1/2 Study of MCLA-128 to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting -
UTRECHT, The Netherlands, April 20, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASD...Read more
argenx receives first preclinical milestone payment in AbbVie collaboration -
Breda, the Netherlands/Ghent, Belgium - April 13, 2017 - argenx (Euronext Br...Read more
Marco Groot over LSP in het FD -
Amsterdam, April 11, 2017
Marco Groot over LSP in het FD
Lees de gehe...Read more
Kuros announces CEO succession -
Commercialization veteran and life science executive Dr. Ivan Cohen-Tanug...Read more
argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients -
Interim data expected by end of 2017
Breda, the Netherlands/Ghen...Read more
15th BioCapital Europe -
March 15, 2017 – The 15th BioCapital Europe Conference took place at the pr...Read more
LSP’s portfolio company Neuravi acquired by Codman Neuro -
Amsterdam, the Netherlands, April 10, 2017 – LSP (Life Sciences Partners), ...Read more
Last Patient Last Visit (LPLV) reached in the SAPHIR Study -
Last Patient Last Visit (LPLV) reached in the SAPHIR Study, a Phase 2 trial w...Read more
argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia -
Breda, the Netherlands / Ghent, Belgium, March 31, 2017 - argenx (Euronext B...Read more
argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases -
Differentiated antibody to address complement target
Represents l...Read more
Merus Named BioCapital Europe 2017 Company of the Year -
Award Recognizes Company’s Substantial Transformation and Breakthroughs Ove...Read more
argenx reports fourth quarter business update and full year 2016 financial results -
Breda, the Netherlands / Ghent, Belgium, March 15, 2017 - argenx (Euronex...Read more
LSP invests in Orphazyme as part of a EUR 14 million Series B extension to further expand clinical programmes -
Amsterdam, The Netherlands, March 15, 2017 - LSP portfolio company Orphazyme ...Read more
LSP takes part in Euronext Amsterdam gong ceremony -
BioCapital Europe, an LSP healthcare conference, will take place for the 15th...Read more
argenx announces that Staten Biotech exercised its option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia -
Anti-ApoC3 antibody developed as part of research collaboration on dyslip...Read more
argenx announces intention to conduct a registered public offering in the United States -
Breda, the Netherlands / Ghent, Belgium, March 1, 2017 - argenx (Euronext Bru...Read more
argenx announces extension of therapeutic antibody alliance with Shire -
Breda, the Netherlands / Ghent, Belgium, February 27, 2017 - argenx (Euronext...Read more
Kuros receives clearance from the US FDA for MagnetOs allowing marketing in the United States -
Schlieren (Zurich), Switzerland, February 27, 2017 - Kuros Biosciences (SIX:...Read more
Neuravi Announces Completion of Patient Enrollment in Clinical Trial of a Novel Stent Retriever for Acute Ischemic Stroke -
ARISE II Data Will Be Submitted to the FDA in Support of Market Clearance for...Read more
Kuros closes acquisition of Xpand creating a leading commercial-stage orthobiologics company -
Schlieren (Zurich), Switzerland, January 25, 2017 - Kuros closes acquisition ...Read more
Curetis’ Global Installed Base Expanding to Over 150 Unyvero Analyzers -
Completion of EMEA Direct Sales team build-out drives 46% growth in syste...Read more
BioCapital Europe 2017, organised by LSP -
BioCapital Europe 2017, organised by LSP, is pleased to announce the keynote ...Read more
LSP’s portfolio company G-Therapeutics named FierceMedicalDevices' 2016 Fierce 15 company -
Amsterdam, The Netherlands, January 23, 2017. It is with great pleasure that ...Read more
Merus Announces Closing of Global Strategic Research Collaboration with Incyte to Discover and Develop Bispecific Antibodies -
UTRECHT, The Netherlands, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDA...Read more
LSP's portfolio company Atlas Genetics raises $35m in Series D fundraising -
Financing global launch and menu development of Atlas Genetics’ io® molecu...Read more
Affimed Announces Pricing of Public Offering of Common Stock -
Heidelberg, Germany January 20, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinica...Read more
LSP's portfolio company Luxendo Announces Series A Extension Bringing Total Capital Raised to €8 Million -
Luxendo intends to use funds to drive the uptake of its Single Plane Illumina...Read more
Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimer's disease patients -
Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study ...Read more
Affimed and MD Anderson Announce Clinical Immuno-Oncology Development Collaboration -
Agreement Brings Together MD Anderson's Natural Killer Cell and Affimed&#...Read more
Curetis Completes Development of Unyvero Cartridge for Intra-Abdominal Infections -
Highly multiplexed panel covers up to 112 diagnostic targets
Third ...Read more
argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravis -
- Topline data from the study expected in second half of 2018 -
Br...Read more
Merus and the Institute for Research in Biomedicine (IRB) Barcelona Form Research Collaboration to Develop Bispecific Antibodies Targeting the Tumor Microenvironment -
UTRECHT, The Netherlands, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDA...Read more
Curetis Files for U.S. FDA Clearance for Unyvero Platform and LRT Application Cartridge -
Final panel demonstrates overall weighted average sensitivity of 91.4% an...Read more
Kuros to acquire Xpand in an all-share strategic transaction to create a leading commercial stage orthobiologics company -
Xpand’s first product MagnetOs, a novel orthobiologic, is approved for ...Read more
LSP’s portfolio company Merus announces global strategic collaboration with Incyte -
LSP’s portfolio company Merus announces global strategic collaboration with...Read more
argenx announces publication of seminal data supporting the therapeutic potential of ARGX-110 for acute myeloid leukemia in the Journal of Experimental Medicine -
Breda, the Netherlands / Ghent, Belgium, December 29, 2016 - argenx (Euronext...Read more
argenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients -
Breda, the Netherlands / Ghent, Belgium, December 15, 2016 - argenx (Euronext...Read more
Kiadis will start trial to treat children with severe blood disorder -
Amsterdam, The Netherlands, December 15, 2016, – Kiadis Pharma N.V. (“Kia...Read more
Curetis Acquires Real-Time qPCR Platform from Carpegen and Systec -
Gyronimo Platform offers rapid, quantitative cartridge-based sample-to-an...Read more
#investEU - Curetis obtains EIB debt financing totaling up to EUR 25 million to further expand its diagnostic platform -
European Investment Bank (EIB) provides EUR 10 million immediately, with ...Read more
LSP led a EURO 32 million investement in OxThera AB -
Amsterdam, the Netherlands, December 9, 2016, OxThera AB, a Stockholm-based p...Read more
Hybrigenics enrolls a first patient in the United States in the clinical study of inecalcitol in acute myeloid leukemia patients unfit for chemotherapy -
Paris, France, 28 November 2016 – Hybrigenics (FR0004153930 - ALHYG), a bio...Read more
Impacting patient lives with new diabetes drug approval -
Amsterdam, Munich, Boston, November 22, 2016 - LSP (Life Sciences Partners), ...Read more
Amyloid-beta (Abeta) aggregate-clearing by the murine anti-pyroglutamate-3 Abeta IgG2a monoclonal antibody PBD-C06 with and without a complement mutation in an Alzheimer's mouse model -
HALLE (SAALE), Germany, 16 November 2016 - Probiodrug AG (Euronext Amsterdam:...Read more
Merus Announces Favorable Decisions in Europe and Japan for Patents Covering Genetically-Modified Mice for Common Light Chain Human Monoclonal Antibodies -
European Patent Office Dismisses Arguments by Regeneron
Favorable Ru...Read more
Wireless brain-spine connection to overcome paralysis -
Prof Grégoire Courtine and Dr. Jocelyne Bloch, both founders of LSP’s port...Read more
Merus strengthens Executive Management Team with the appointment of John Crowley as Chief Financial Officer -
UTRECHT, The Netherlands, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDA...Read more
Merus N.V. Receives €1.5 Million EUREKA Eurostars Grant with Aquila BioMedical Ltd to Jointly Develop Immunological Assays for Identification of Novel Immunomodulatory Bispecific Antibodies -
UTRECHT, The Netherlands and EDINBURGH, UK, Nov. 09, 2016 (GLOBE NEWSWIRE) --...Read more
Merus Expands Executive Management Team with the Appointment of L. Andres Sirulnik, MD, PhD, as Chief Medical Officer -
UTRECHT, The Netherlands, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDA...Read more
Curetis Announces Positive Top Line Data from U.S. FDA Trial -
Primary endpoint for Unyvero LRT product for lower respiratory tract infe...Read more
Merus Receives Milestone Payment from Ono Pharmaceutical for Selection of Bispecific Antibody Candidate for Clinical Development and Extends Partnership with CMC Service Agreement -
UTRECHT, The Netherlands, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDA...Read more
Probiodrug announces pricing of a EUR 14.9 million accelerated bookbuild offering of new shares -
NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, JAP...Read more
Immunic acquires 4SC’s Immunology Portfolio -
Immunic acquires two promising drug development programs with validated targe...Read more
Nouscom Appoints New Chief Operating Officer and Strengthens the Board of Directors -
Basel, Switzerland – 26 September 2016: Nouscom, an oncology company develo...Read more
argenx provides update on lead programs in auto-immune disease and oncology at R&D day in New York -
Myasthenia gravis and immune thrombocytopenia named as initial indication...Read more
LSP Venture Partner Hans Clevers gets prestigious “Körber Award” for his ground breaking research into stem cells and organoids, and appears in German prime time television news -
To see the video click here
...Read more
LSP Leads EUR 16.2M Financing Round in Vivasure Medical to Advance Commercialization of its Closure Device in the European Union and entry into the United States -
Amsterdam, the Netherlands —September 8, 2016 — LSP (Life Sciences Partne...Read more
Neuravi Announces European Launch of EmboTrap II Stent Retriever for the Treatment of Acute Stroke -
Advancements to Stent Retriever Platform Designed to Enhance Procedure
...Read more
Promising new findings for Probiodrug's Glutaminyl Cyclase - inhibitor in an inflammation animal model -
Promising new findings for Probiodrug's Glutaminyl Cyclase - inhibitor in...Read more
ViCentra appoints two new medical and scientific advisors -
6th September 2016
ViCentra, manufacturer of the Kaleido insulin d...Read more
Curetis to Launch Next Generation CE-IVD Unyvero Implant and Tissue Infection Application Cartridge -
Launch follows successful completion of CE Performance Evaluation Study
...Read more
LSP’s Portfolio Company Mint Solutions Raises € 5 Million in Series B Financing Round -
Amsterdam, the Netherlands, August 25, 2016 – LSP’s portfolio company Min...Read more
argenx Reports Second Quarter Business Update and Half Year 2016 Financial Results -
Successful Phase 1 multiple ascending dose (MAD) study of ARGX-113 in hea...Read more
Kiadis featured in German "Aktionärsbrief" -
Click here to see the full article.
...Read more
Curetis Completes Sample Enrollment in Unyvero U.S. FDA Trial in Lower Respiratory Tract Infections -
Last patient enrolled in prospective arm of IVD trial
More than 2...Read more
Curetis Announces Excellent Study Data and Multi-Region Launch of Unyvero BCU Blood Culture Application Cartridge -
- Interim data from prospective multicenter evaluation show 98% concordance w...Read more
argenx announces efficacy and expanded safety data from Phase 1 trial of ARGX-111 -
Additional preclinical data support potential of ARGX-111 in targeting tumor ...Read more
Merus Signs Commercial Multi-Product License for ProBioGen’s GlymaxX® ADCC Enhancement Technology -
Bispecific Cancer Antibody Pipeline Optimized by GlymaxX® Manufacturing Tech...Read more
argenx announces private placement of 2,703,000 new shares for an aggregate amount of €30 million with institutional investors -
Breda, the Netherlands / Ghent, Belgium - June 01, 2016 – argenx (Euronext...Read more
LSP’s portfolio company Merus listed on NASDAQ -
Our portfolio company Merus, based in Utrecht, the Netherlands, got liste...Read more
Nouscom concludes successful series A financing of EUR 12 million -
Basel, Switzerland – May, 17 2016 -- Nouscom announced today that it has cl...Read more
eTheRNA strengthens management team with appointment of Dr. Karl-Josef Kallen as Chief Medical Officer -
eTheRNA immunotherapies, the VUB spin-off that recently secured a EUR 24 mi...Read more
Merus Announces First Patient Dosed in Phase 1/2 Trial Evaluating Bispecific Antibody Candidate MCLA-117 in Patients with AML -
UTRECHT, The Netherlands, May 04, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clin...Read more
LSP’s portfolio company argenx and AbbVie to collaborate on ARGX-115 against novel immuno-oncology target -
Amsterdam, the Netherlands – 21 April 2016 – AbbVie (NYSE: ABBV), a globa...Read more
LSP co-leads Series A financing of G-Therapeutics that raises EUR 36 mln to develop its neuro-stimulation therapy for spinal cord injury -
Amsterdam, the Netherlands – 19 April 2016 – G-Therapeutics announces tod...Read more
Merus to Present Interim Clinical Data from Ongoing Phase 1/2 Clinical Trial of its Lead Bispecific Antibody Candidate, MCLA-128, at the American Association for Cancer Research 2016 Annual Meeting -
MCLA-128 Shows Favorable Safety Profile and Early Signs of Anti-Tumor Activit...Read more
New topinstitute for cancer launched in The Netherlands -
The Netherlands has a very strong science base in for example oncology, but t...Read more
Kiadis Pharma proposes Robert Soiffer and Berndt Modig as its new Supervisory Board members -
Amsterdam, The Netherlands, April 7, 2016 – Kiadis Pharma N.V. (“Kiadis P...Read more
Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101™ -
Significant increase in Overall Survival and reduction in Transplant Rela...Read more
Curetis to Launch CE-IVD Unyvero Blood Culture Application Cartridge at ECCMID 2016 -
- Successful completion of CE Performance Evaluation Study
- Covers 103 d...Read more
Probiodrug Appoints Mark Booth as Chief Business Officer -
Expands Management Board with Senior Hire
HALLE/SAALE, Germany, 23...Read more
ETheRNA, een spin-off van de VUB, werkt aan een immuuntherapie met een 'drievoudige boost' -
ETheRNA, een spin-off van de VUB, werkt aan een immuuntherapie met een 'd...Read more
Bio€quity 2016 -
LSP is a sponsor of the Bio€quity Europe 2016 in Copenhagen, Denmark.
T...Read more
LSP leads EUR 24 mln Series A financing of eTheRNA to develop its TriMix mRNA-based immunotherapy -
Amsterdam, the Netherlands – 14 March 2016 – eTheRNA immunotherapies, a s...Read more
TiGenix announces positive 52-week Phase III results of Cx601 in complex perianal fistulas in Crohn's disease patients -
A single injection of Cx601 was statistically superior to placebo in achi...Read more
Curetis Starts Final Validation Study for New Unyvero Blood Culture Application Cartridge -
- Data and CE-IVD launch expected in Q2, 2016
- Company also prepar...Read more
First full hospital roll-out of MedEye in the Netherlands -
LSP’s portfolio company Mint Solutions provides for the first time an entir...Read more
Digital health and medtech come alive -
Healthcare investing comes of age
The stage is all set for another good ...Read more
Atlas Genetics Gains CE Approval for First Product -
Approval of Chlamydia test for marketing and sale in Europe
Bath, ...Read more
LSP’s Nexstim and its impact in brain surgery -
For more info click here
...Read more
Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes -
The Phase 2 trial is an important step in the dual product development of...Read more
Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Hodgkin Lymphoma -
Heidelberg, Germany, January 25, 2016 - Affimed N.V. (Nasdaq: AFMD), a clin...Read more
Curetis Expands Commercial Team -
- Company hires Willem Haagmans as Head of Sales EMEA -
Amsterdam,...Read more
Agenus Announces Clearance of Investigational New Drug Applications by the FDA for anti-CTLA-4 and antiGITR Antibodies -
Clinical studies for both checkpoint modulator antibodies allowed to commence...Read more
LSP’s portfolio company Kuros closes merger with Cytos and is now listed as Kuros Biosciences Ltd on Swiss stock exchange -
Amsterdam, the Netherlands – 20 January 2016 – Our portfolio company Kuro...Read more
argenx announces € 16 M investment by US funds advised by subsidiaries of Federated Investors -
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOL...Read more
LSP Leads Financing Round in Insulin Pump Company ViCentra -
Amsterdam, the Netherlands, 20 January 2016. LSP (Life Sciences Partners), a ...Read more
Merus and Gustave Roussy Form Strategic Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Immuno-Oncology Applications -
UTRECHT, The Netherlands and VILLEJUIF, France, Jan. 04, 2016 (GLOBE NEWSWIRE...Read more
Sanofi Submits New Drug Application for the Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide -
Paris, France - December 23, 2015 - Sanofi announced today that it has submit...Read more
Nexstim announces the result of its private placement -
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR...Read more
Xeltis extends series B financing to €30M, signing off transformational year -
In 2015: positive results from first two clinical trials, stronger leadership...Read more
Merus Appoints Hui Liu as Chief Business Officer -
Novartis Oncology’s Former Global Head of Business Development and Licensin...Read more
Affimed Added to NASDAQ Biotech Index® -
Heidelberg, Germany, December 14, 2015 - Affimed N.V. (Nasdaq: AFMD), a clini...Read more
Probiodrug announces publication of initial PQ912 clinical data demonstrating inhibition of glutaminyl cyclase -
PQ912 is currently in Phase 2a studies in Alzheimer’s disease patients
...Read more
Hybrigenics receives green light for a double-blind placebo-controlled Phase II clinical study of inecalcitol in Acute Myeloid Leukemia (AML) -
Hybrigenics has received the authorization by the French Drug Agency to p...Read more
Nexstim Plc Announces Completion of Enrolment of Phase III Clinical Trial in Stroke Therapy -
- Recruitment completed ahead of schedule
Helsinki, 3 December 201...Read more
LSP V company Kuros to combine with Cytos -
Cytos Biotechnology and Kuros Biosurgery to combine to create Kuros Bioscienc...Read more
LSP and Bristol-Myers Squibb enter into strategic collaboration for life sciences innovation in Europe -
First investment by Bristol-Myers Squibb in a European healthcare fund
...Read more
LSP: A European Venture Fund Invests in the Economics of Medtech -
Amsterdam, 17 November 2015 – For a recent in-depth article on the LSP Heal...Read more
Xeltis completed second feasibility clinical trial on bioabsorbable cardiovascular device technology -
Xeltis developing first cardiac valves and vessels designed to allow endogeno...Read more
LSP’s portfolio company Curetis raises EUR 40 million in successful Euronext IPO -
Amsterdam, the Netherlands - 12 November 2015 - Our portfolio compan...Read more
Probiodrug announces pricing of a EUR 13.5 million private placement of new shares -
NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, JAP...Read more
Kiadis Pharma announces maiden Financial Results for the six months ended 30 June 2015 -
Amsterdam, The Netherlands, August 25, 2015 – Kiadis Pharma N.V. (“Ki...Read more
LSP invests in Kuros, a late-stage sealant and orthobiologics company -
Amsterdam, The Netherlands, 18 August 2015. LSP (Life Sciences Partners), a l...Read more
Merus enters into 72.8 million euro series C financing led by Sofinnova Ventures and Novo A/S -
UTRECHT, Netherlands, Aug. 26, 2015 /PRNewswire/ -- Merus B.V., a clinical-st...Read more
LSP raises EUR 80 mln to invest in medical innovations -
Not for distribution or release directly or indirectly, in or into the Un...Read more
Can we train our bodies to fight cancer? -
While tremendous strides have been made in the fight against cancer – the b...Read more
Kiadis Pharma Announces Full Enrolment of its Phase II Clinical Study with Lead Product, ATIR101™ -
~ The target 23 patients have now been enrolled ~
Amsterdam, the N...Read more
Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH) - - MYDICAR When Inhaled May Restore Function of SERCA2a Enzyme in the Lungs to Re...Read more
Celladon's gene therapy for heart failure takes spotlight in the U.K. - By John Carroll, FierceBiotech
San Diego-based Celladon has made a big splash...Read more
Prosensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer -
Leiden, The Netherlands, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Prosensa Holding N...Read more
Hybrigenics revenues grew 45% to EUR 6.6 million in 2011 - Hybrigenics Services contributed for EUR 4.1 million, a 17% growth
In 2011, H...Read more
Former LSP company Okairos working on Ebola -
A link to the press release can be found here
...Read more
Celladon Corporation Announces First Patient Dosed in CUPID Phase 2b Trial of MYDICAR® for Advanced Heart Failure - San Diego, California, August 29, 2012/PRNewswire/ -- Celladon Corporation, a bi...Read more
Zealand and Boehringer Ingelheim sign second collaboration agreement to advance novel peptide medicines -
─ Zealand eligible to receive up to EUR 295 million in potential milestone ...Read more
arGEN-X presents preliminary efficacy and expanded safety data from Phase I trial of ARGX-111 at ASCO -
Safe dose established for next stage studies
Biological activity ...Read more
GSK strengthens vaccines business with acquisition of Okairos - Issued: Wednesday 29 May 2013, London UK
GSK strengthens vaccines business wi...Read more
Celladon Corporation Selected as Winner of Red Herring's "Top 100 North America Tech Startup" - SAN DIEGO, May 29, 2013 /PRNewswire/ -- Celladon Corporation, a biopharmaceutica...Read more
LSP leads a CHF 23 million Series C investment in Sequana Medical -
Amsterdam, The Netherlands, 28 April 2014. LSP (Life Sciences Partners), a le...Read more
AGENUS ANNOUNCES COLLABORATION AND LICENSE AGREEMENT WITH MERCK FOR NOVEL CHECKPOINT ANTIBODY-BASED CANCER IMMUNOTHERAPIES -
• Agenus is eligible to receive ~$100 million in milestone payments as well...Read more
Bryan, Garnier & Co initiates coverage of Hybrigenics with a target price of €2.6 - Paris, March 29, 2012 – Hybrigenics SA (ALHYG), a bio-pharmaceutical company l...Read more
arGEN-X enters into a therapeutic antibody alliance with Shire - HUMAN ANTIBODY PRODUCT COLLABORATION IN RARE DISEASES
Rotterdam, the Netherla...Read more
Prosensa Achieves Orphan Drug Status on its Entire Duchenne Muscular Dystrophy Portfolio - Leiden, The Netherlands – 29 January 2013 – Prosensa, the Dutch biopharmaceu...Read more
4-Antibody AG and the Ludwig Institute Expand Oncology Antibody R&D Program with Three New Targets - Basel, Switzerland and New York, NY, 29 Jan, 2013: 4-Antibody AG and the Ludwig ...Read more
Okairos named as one of Windhover’s Top Projects to Watch in infectious diseases - Basel, Switzerland – 28 November 2012 – Windhover Information has named Okai...Read more
LSP Health Economics Fund co-leads $28 Million Series C Financing round of IlluminOss - Amsterdam - Boston – September 28, 2012 – LSP Health Economics Fund is pleas...Read more
Nexstim Progresses its Navigated Brain Stimulation Technology in Stroke and Demonstrates Improved Outcomes in Brain Tumor Surgery -
• Study on track and sites selected and initiated in multicenter clinical t...Read more
Prosensa Announces Second Quarter 2013 Financial Results and Recent Corporate Developments - Raised $89.7M with successful IPO, providing substantial base to support develop...Read more
LSP company Prosensa successfully listed on NASDAQ -
It is with great pleasure that today, LSP – the specialist European healthc...Read more
Lyxumia® is first diabetes therapy of its class approved in Japan for use in combination with basal insulin - - First once-daily prandial GLP-1 receptor agonist offering a new treatment opti...Read more
arGEN-X announces collaboration with Bayer to discover and develop therapeutic antibody candidates -
Breda, the Netherlands, 28 May 2014 – arGEN-X, a clinical-stage biopharmace...Read more
LSP portfolio company Agenus in the press -
Please find two links to press releases issued this week by Agenus www.agenus...Read more
Hybrigenics full year 2014 results -
Strong cash position further recently increased by EUR 9 million
Par...Read more
BioCapital Europe - Presenting companies announced -
BioCapital Europe, Europe's premier life sciences investment conference ...Read more
Leve de wetenschap -
De Nederlandse wetenschap is top. Durfinvesteerder LSP schrijft het nog eens ...Read more
LSP's portfolio company EyeSense enters strategic partnership with Lee’s Pharmaceutical Holdings -
Through the attached press release we are happy to announce the strategic par...Read more
Curetis AG Signs Up BioLine LLC as Exclusive Distribution Partner for Russia - Partners to start registration process and market launch in Russia
Holzgerlin...Read more
Biotech Update 2013 - Biotech Update 2013
Friday 28th June 2013
Kasteel De Wittenburg in Wassenaar, ...Read more
SUPPRESTEM Consortium Led by Merus Receives €6 Million FP7 Grant from the European Union - - Development of Therapeutic Bispecific Antibodies (Biclonics™) Targeting Trea...Read more
BioCapital Europe takes place today in Amsterdam -
John P. de Koning, Partner at LSP and conference host, sounded the bell yeste...Read more
Hybrigenics completed its private placement to institutional investors up to EUR 3.3 million - Paris, March 27, 2012 - Hybrigenics SA (ALHYG), a bio-pharmaceutical company lis...Read more
Prosensa Receives Rare Disease Company Award from EURORDIS - Leiden, The Netherlands – 27 February 2013 – Prosensa, the Dutch biopharmace...Read more
Hybrigenics extends its partnership with Servier in the field of Ubiquitin-Specific Proteases inhibitors -
Paris, 26 January 2015 – Hybrigenics (ALHYG), a bio-pharmaceutical company ...Read more
Curetis AG Chooses Mediphos as Exclusive Distribution Partner for the Netherlands - Partners prepare market launch and clinical evaluation project
Holzgerlingen,...Read more
LSP’s portfolio company Sapiens Steering Brain Stimulation acquired by Medtronic for EUR 150 million -
Amsterdam, the Netherlands, 26 August 2014. LSP (Life Sciences Partners), a l...Read more
arGEN-X to Present at Upcoming Ninth Annual PEGS 2013 - Presentations will highlight significant progress made towards development of no...Read more
BioCapital Europe Company of the Year award goes to Prosensa -
Amsterdam, March 26, 2015. At the BioCapital Europe conference being held tod...Read more
--- BIOCAPITAL EUROPE INVESTOR CONFERENCE TO TAKE PLACE ON 27TH MARCH 2014 -
BioCapital Europe 2014, organised by LSP (Life Sciences Partners) is delighte...Read more
Een druppel op de hete financiële gezondheidsplaat -
Het jonge Nederlandse fonds LSP Health Economics Fund heeft 113 miljoen euro ...Read more
Kiadis Pharma Receives Regulatory Approval from Health Canada for a Phase II Clinical Study with its Blood Cancer Treatment ATIR™ - Amsterdam, The Netherlands, February 26, 2013 – Kiadis Pharma B.V., a clinical...Read more
arGEN-X appoints Dr. David L. Lacey to its Supervisory Board - Breda, the Netherlands and Ghent, Belgium October; 25 October 2012 – arGEN-X, ...Read more
OctoPlus announces equity raising with net proceeds of € 3 million -
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CA...Read more
Affimed Announces Financial Results for Fourth Quarter and Year End 2014 -
--Transformative Year for the Company and its Bi- and Trispecific Cancer Immu...Read more
arGEN-X announces preclinical development of ARGX-112 for dermatology - ARGX-112 targets IL22R1, a novel target involved in chronic skin inflammation
...Read more
Okairos initiates Phase I clinical trial evaluating vaccine against RSV infections - Basel, Switzerland – 25 February 2013 – Okairos today announced the initiati...Read more
Prosensa Raises €23 Million in New Equity Financing Led by New Enterprise Associates - Leiden, The Netherlands, 25 January 2012 – Prosensa, the Dutch biopharmaceutic...Read more
LSP's portfolio company Prosensa receives tender offer from BioMarin -
Through the attached press release we are very happy to announce the agreemen...Read more
LSP invests in Curetis, a leading molecular diagnostics company -
Amsterdam, the Netherlands, 24 November 2014. LSP (Life Sciences Partners), a...Read more
LSP’s Portfolio Company Probiodrug listed on Euronext Amsterdam -
Our portfolio company Probiodrug AG, based in Halle/Saale, Germany, ...Read more
Curetis’ Unyvero System Selected for Global Phase III Antibiotics Trial -
• Unyvero to be used for pathogen identification and patient inclusion at s...Read more
New Favorable Clinical Evaluation Data for Unyvero™ P50 Pneumonia Application -
Dutch study demonstrates excellent sensitivity of Unyvero™ cartridges ...Read more
arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders - First program based on proprietary ABDEG™ technology to promote degradation an...Read more
Hybrigenics’ specific inhibitors of Ubiquitin-Specific Protease 7 (USP7) are cytotoxic for human cancer cell lines in vitro - The mechanism of USP7 inhibition and the resulting decrease in viability of huma...Read more
arGEN-X granted first US patent covering its unique NHance™ technology - Rotterdam, the Netherlands and Ghent, Belgium April 24, 2012 – arGEN-X, a biop...Read more
Affimed Completes TandAb Development Candidate Activities Meeting Amphivena's and Janssen's Criteria and Achieves Milestone Ahead of Schedule -
-- Cancer Immunotherapy Development Candidate Selection Triggers Milestone Pa...Read more
Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR™ - Amsterdam, The Netherlands, January 21, 2013 – Kiadis Pharma B.V., a clinical ...Read more
TiGenix secures EUR 10 million in financing from Kreos Capital Company ends year in strong position to fully leverage leading cell therapy platform - Leuven (BELGIUM) – December 23, 2013 – TiGenix (Euronext Brussels: TIG) anno...Read more
Merus Granted European Patent on MeMo®, a Transgenic Mouse for Generating the Building Blocks of Therapeutic Human Bispecific Antibodies - - Invention provides unique technology base for therapeutic human bispecific ant...Read more
Prosensa Announces Progress on Exon Skipping Compounds for the Treatment of Duchenne Muscular Dystrophy - £10m in milestone payments received from GlaxoSmithKline
Leiden, The Netherl...Read more
Kiadis Pharma to receive GMP manufacturing license and GMP certificate - Amsterdam, The Netherlands, July 23, 2013 – Kiadis Pharma B.V., a clinical sta...Read more
arGEN-X Announces Publication on Therapeutic Potential of Antibody ARGX-115 in Cancer Immunotherapy -
Results on ARGX-115 published in Science Translational Medicine indicating in...Read more
Save the Date: BioEquity Europe 2012 - May 15-16 - BioEquity Europe 2012
May 15-16, 2012
Frankfurt (Main), Germany...Read more
Save the Date: BioTech Update 2012 - June 12 - BioTech Update 2012
June 12th
Wassenaar, The Netherlands...Read more
Probiodrug AG Strengthens Management Team and Expands Global Reach with Appointments of Ronald Black and Inge Lues - HALLE/SAALE, Germany, January 23, 2013 – Probiodrug AG (Probiodrug) today anno...Read more
Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office - -Patent will provide IP protection relative to Celladon's small molecule program...Read more
Hybrigenics 2013 first-half results Update on the development of inecalcitol -
+9% growth of Hybrigenics’ operating revenues
60% biological respo...Read more
Curetis Presents First Data on Novel Unyvero™ i60 ITI Application for Implant and Tissue Infections - New cartridge detects 114 targets
Roll-out in collaboration with Heraeus Medi...Read more
Hybrigenics’ inecalcitol receives positive opinion from EMA for orphan drug designation in acute myeloid leukemia -
Paris, 22 June 2015 – Hybrigenics (ALHYG), a bio-pharmaceutical company lis...Read more
Prosensa wins “Emerging Star Award” at the European Mediscience Awards - Leiden, The Netherlands, 22 June 2012 - Prosensa, the Dutch biopharmaceutical co...Read more
STALLERGENES AND ACTOGENIX TO DEVELOP AN INNOVATIVE NEW CLASS OF ORAL ALLERGY TREATMENTS -
STALLERGENES exercised option to pursue the exclusive development of applicat...Read more
arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions -
Breda, the Netherlands/Ghent, Belgium and Ballerup, Denmark, May 21, 2015 –...Read more
Hybrigenics launches Phase II clinical study of inecalcitol in chronic myeloid leukemia -
Paris, 19 January 2015 – Hybrigenics (ALHYG), a bio-pharmaceutical company ...Read more
Zorgverzekeraars stappen massaal in nieuw fonds -
Door Hans Maarsen
Life Sciences Partners in Amsterdam, behorend tot de gr...Read more
Should I have my DNA analyzed? -
By Geraldine O'Keeffe
According to the advertisement, for as little ...Read more
Prosensa listed on NASDAQ raising $ 100 million -
It is with great pleasure that today, LSP – the specialist European healthc...Read more
Kiadis Pharma Raises EUR 10 Million in Financing Round - Amsterdam, The Netherlands, November 20, 2012 – Kiadis Pharma B.V., a clinical...Read more
SAVE THE DATE: Biotech Update 2013 - Biotech Update 2013
Friday 28th June 2013
Kasteel De Wittenburg in Wassenaar, ...Read more
BioCapitalEurope 2013 - BioCapitalEurope
Wednesday 17th April 2013
BioCapital Europe 2013, organis...Read more
Pasteuria Bioscience to be Acquired by Syngenta - Amsterdam and Boston, September 20, 2012 - LSP is pleased to announce that Synge...Read more
Curetis and Heraeus Medical Collaborate on the Development of New Unyvero™ Diagnostic Cartridge - Joint development of cartridge for orthopaedics, wound and surgery infections
...Read more
Hybrigenics’ inecalcitol shows synergy with azacytidine in preclinical models of Acute Myeloid Leukemia -
Results are presented today at the 17th Vitamin D Workshop in Chicago, USA
...Read more
Merus receives EP patent covering the expression of defined antibody combinations - Utrecht, The Netherlands, June 20, 2012 – Merus B.V., a biopharmaceutical comp...Read more
Merus and Selexis receive a € 2.1 million grant for single cell line manufacturing of a bispecific antibody combination to treat colorectal cancer -
Utrecht, The Netherlands, May 20, 2015 -- Merus B.V., a leader in developing ...Read more
Hybrigenics’ inecalcitol gets Orphan Drug designation for the treatment of Chronic Lymphocytic Leukemia in the United States -
Paris, 20 May 2014 : Hybrigenics (ALHYG), a bio-pharmaceutical group list...Read more
Hybrigenics Services wins the Life Science Award of the “Most Innovative New Service” of the yearat the 4th annual European Lab Automation Exhibition -
Paris, 19 May 2014 – Hybrigenics (ALHYG), a bio-pharmaceutical group listed...Read more
Exciting stuff at the BioCapital Europe 2015 Conference -
March 26, LSP organized the BioCapital Europe Conference for the 13th consecu...Read more
arGEN-X launches NHance™ technology to generate better human antibody therapies - adds a second proprietary technology to leverage the power of the SIMPLE Antibod...Read more
Pronota announces EUR 3.7 million Series C financing; management and board changes - Ghent, Belgium; Pronota NV today announced the close of a Series C financing, ra...Read more
Menzis investeert met LSP Health Economics Fund in zorginnovaties - Amsterdam, 19 oktober 2012 – Dit voorjaar werd het LSP Health Economics Fund (...Read more
arGEN-X completes recruitment of first cohort of 15 patients with CD70-positive solid tumors into its Phase 1b expansion trial with ARGX-110 -
18 September 2014
Breda, the Netherlands / Ghent, Belgium - arGEN-...Read more
Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech - San Diego, California, September 19, 2012/PRNewswire/ -- Celladon Corporation, a...Read more
Three LSP portfolio companies nominated to the 2012 Fierce 15 list - Amsterdam, September 19, 2012 – Life Sciences Partners (LSP), the European hea...Read more
Celladon Corporation Receives Patent from United States Patent and Trademark Office - -Patent will further expand intellectual property protection for MYDICAR® – a...Read more
Biotech Update Wassenaar -
We have seen a very successful year for the life science industry with an...Read more
Probiodrug receives 2015 European Mediscience Award for Best Technology -
HALLE/SAALE, Germany, 12 June 2015 – Probiodrug AG (Euronext Amsterdam: PBD...Read more
LSP’s Clemens van Blitterswijk welcomes the King at MERLN -
LSP’s Clemens van Blitterswijk welcomes the King at MERLN
http://www.m...Read more
Hybrigenics targets chronic lymphocytic leukemia (CLL) as the third therapeutic indication for its oral inecalcitol - Hybrigenics filed a clinical trial application to test inecalcitol, a vitamin D ...Read more
LSP raises € 112 mln for its Health Economics Fund, exceeding target -
Amsterdam, The Netherlands, 7 March 2014. LSP (Life Sciences Partners), a lea...Read more
Nexstim Launches Next Generation NBS 5 System -
Helsinki, 18 September 2014
Nexstim (the “Company”), a medical...Read more
Activaero’s partner ablynx initiated phase I studies in Respiratory Syncytial Virus (RSV) using favorite technology -
Gemuenden/Wohra, Germany, July 18, 2013 - Activaero GmbH, the therapeutic are...Read more
Curetis AG Signs Distribution Deal in Middle East with ATC - Holzgerlingen, Germany, July 18, 2012 -- Curetis AG, an innovative molecular dia...Read more
arGEN-X presents preliminary Phase I results of ARGX-110 in patients with T-cell lymphomas at ICML -
Breda, The Netherlands / Ghent, Belgium, June 17, 2015 - arGEN-X N.V. (Eu...Read more
Celladon Corporation Receives Notice of Allowance from European Patent Office - -Patent will expand intellectual property protection for MYDICAR – a first in ...Read more
Merus announces appointment of Jason Avery as Chief Business Officer - Utrecht, The Netherlands, June 15, 2012 – Merus B.V., a biopharmaceutical comp...Read more
MDD Interview: Nexstim targets $1.8B with brain stimulation for stroke therapy -
Europe Editor
On the strength of a 29-patient Phase II clinical study th...Read more
ActoGeniX closes EUR 10.7 million financing round - ActoGeniX, a clinical stage biopharmaceutical company, successfully closed a Ser...Read more
Better diagnosis of acute heart failure using Pronota’s novel biomarker -
Two independent validation studies demonstrate that Pronota’s biomarker CD1...Read more
ARGX-110, a novel anti-CD70 antibody, meets translational development goals in dose escalation part of Phase Ib cancer study - Dose confirmed for Phase Ib safety and efficacy expansion study
17 December 2...Read more
ActoGeniX Announces Positive Results From a Phase 1 Study of AG014; Oral Capsule Administration of an Anti-TNF-Alpha Antibody for the Treatment of Inflammatory Bowel Disease -
AG014 Safe and Well Tolerated, Successful Localized GI Delivery of Drug With
...Read more
ARGEN-X initiates phase Ib study of ARGX-111 in cancer -
SIMPLE Antibody™ with unique mode of action addressing c-Met positive tumor...Read more
LSP leads EUR 19M Financing Round in Endovascular Stroke Company Neuravi -
Amsterdam, the Netherlands, 17 June 2015. LSP (Life Sciences Partners), a lea...Read more
Merus Presents Preclinical Data on its Novel Bispecific Antibody MCLA-117 at EHA 2013 - - Clinical Candidate Designed for the Treatment of Acute Myeloid Leukemia (AML) ...Read more
Save the Date: BioCapital Europe 2012 - April 19 -
BioCapital Europe 2012, organised by LSP (Life Sciences Partners) and ABN AM...Read more
Hybrigenics’ inecalcitol receives positive opinion from EMA for orphan designation in chronic lymphocytic leukemia - Paris, 16 December 2013 – Hybrigenics (ALHYG), a bio-pharmaceutical company li...Read more
Affimed Therapeutics and The Leukemia & Lymphoma Society Partner to Advance AFM13 in a Phase 2 Trial for Refractory and/or Relapsed Hodgkin Lymphoma Patients - Heidelberg, Germany, and White Plains, NY, USA, September 16th, 2013: Affimed Th...Read more
Hybrigenics gives an update on the clinical development of inecalcitol -
· End of Phase II study in chronic lymphocytic leukemia (CLL)
· Authori...Read more
Probiodrug Provides Update on Clinical Development of PQ912, its Most Advanced QC-inhibitor for Alzheimer’s Disease - HALLE/SAALE, Germany, July 16, 2013 – Probiodrug AG (Probiodrug) today provide...Read more
Pronota Strengthens Management Team - Former VP Corporate Development Genzyme joins as CBO
Ghent, Belgium, 16 March...Read more
LSP’s portfolio company ActoGeniX to be acquired by Intrexon -
Amsterdam, the Netherlands, 13 February 2015. LSP (Life Sciences Partners), a...Read more
Curetis AG Initiates Prospective Clinical Trial for Rapid Pneumonia Diagnostics - Expected CE-marking and launch in Europe in 2012
Holzgerlingen, Germany, Febr...Read more
arGEN-X Completes Recruitment of First Cohort of 15 Patients with CD70-Positive Hematological Malignancies into its Phase 1b Expansion Trial with ARGX-110 -
Based on evidence of activity, T-cell lymphomas selected as indication for in...Read more
LSP's portfolio company Seahorse Bioscience to be acquired by Agilent Technologies -
Amsterdam - 14 September 2015 - LSP (Life Sciences Partners), a leading Europ...Read more
LSP’s portfolio company Affimed listed on NASDAQ -
Munich/Amsterdam, 15 September 2014. It is with great pleasure that today, LS...Read more
LSP's portfolio company Syntaxin sold to Ipsen - LSP, the specialist European healthcare investor, is proud to announce today the...Read more
Amphivena, a Subsidiary of Affimed AG, Completes $14 Million Equity Financing and Signs Agreement with Janssen - Heidelberg, Germany, July 15th, 2013: Affimed Therapeutics AG, the therapeutic T...Read more
Affimed to Present Data at ASCO to Highlight Potency of NK-Cell-Engaging Combination Therapy with Checkpoint Modulators -
--Further Posters to be Presented on Translational Data for CD33/CD3-TandAb P...Read more
Mayo Clinic’s Dr. Robin Patel Named Principal Investigator for Curetis’ Unyvero™ LRT Trial -
- Curetis adds six new trial sites, significantly expanding U.S. clinical tri...Read more
arGEN-X - Third Quarter Business Update -
Breda, The Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: AR...Read more
LSP co-leads Luxendo Series A financing round -
Amsterdam, The Netherlands, October 14, 2015 – Luxendo, a start-up company ...Read more
arGEN-x N.V. Announces Changes to the Board of Directors -
Breda, The Netherlands / Ghent, Belgium, April 14, 2015 - arGEN-X N.V. (Euron...Read more
Okairos announces initiation of Phase I/II clinical trial for potential first-in-class hepatitis C vaccine - Basel, Switzerland – 14 March 2012 – Okairos today announced the initiation ...Read more
OcellO and Merus sign agreement for screening bispecific cancer antibodies - Leiden and Utrecht, The Netherlands, January 14, 2013 - OcellO B.V. and Merus B....Read more
Henri Termeer joins Prosensa as Strategic Advisor - Leiden, The Netherlands – 13 December 2012 – Prosensa, the Dutch biopharmace...Read more
Nexstim launches its Initial Public Offering and will apply for dual listing on Nasdaq First North Finland and Nasdaq First North Sweden -
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR...Read more
LSP Portfolio company Harvest Automation featured on Bloomberg TV - Harvest Automation, a portfolio company of the LSP Bioventures fund, is featured...Read more
Skyline Diagnostics BV and LabPMM GmbH are proud to announce a new commercial testing service for Acute Myeloid Leukemia (AML) patients in Europe - As of June 15, 2012, a comprehensive molecular diagnostic testing service is ava...Read more
Affimed N.V. Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares -
Heidelberg, Germany, May 12, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical-s...Read more
Probiodrug reports First Quarter 2015 Business Update -
HALLE/SAALE, Germany, 13 May 2015 – Probiodrug AG (Euronext Amsterdam: PBD)...Read more
Are we becoming allergic to our planet? -
Over the past 50 years rapid technological advances and rising standards of l...Read more
LSP invests in Cardiac Dimensions, a pioneer in heart failure treatment -
Amsterdam, the Netherlands, March 13 2015. LSP (Life Sciences Partners), ...Read more
Hybrigenics gets approval and financing for a Phase II clinical trial of oral inecalcitol in chronic lymphocytic leukemia (CLL) - The French drug agency approves a Phase II study of oral inecalcitol in CLL, an ...Read more
ARGEN-X identifies potent antibody antagonists against complex chronic pain target Nav1.7 -
Breakthrough data to be presented during the ‘Discovery on Target’ confer...Read more
Curetis Strengthens Executive Team; Appoints Dr. Achim Plum as Chief Commercial Officer -
• Former Siemens Healthcare manager adds broad expertise in molecular diagn...Read more
LSP sounds the opening bell of the NYSE Euronext Stock Exchange - https://www.youtube.com/watch?v=0zdV3vCSfXE&feature=player_embedded
See also ...Read more
TiGenix to obtain national reimbursement in Spain for its innovative cartilage therapy ChondroCelect® - Leuven (BELGIUM), Madrid (SPAIN) – March 12, 2013 – TiGenix NV (Euronext Bru...Read more
Activaero initiates proof of concept trial with Lasag in severe influenza -
Gemünden/Wohra, Germany, February 12, 2013: Activaero GmbH, the therapeutic ...Read more
arGEN-X Launches Innovative Access Program -
Program extends reach of proprietary SIMPLE Antibody™ platform and creates ...Read more
arGEN-X Announces Advancement of Therapeutic Antibody Alliance with Shire -
Shire to take one or more collaborative product candidates into preclinical d...Read more
GSK strengthens vaccines business with acquisition Okairos for € 250 million -
GlaxoSmithKline (GSK) today announced that it has acquired Okairos AG (Okairo...Read more
Celladon Corporation Announces First European Patient Dosed in CUPID Phase 2b Trial of MYDICAR® for Advanced Heart Failure - SAN DIEGO, Dec. 11, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutic...Read more
arGEN-X Initiates Clinical Efficacy Evaluation of ARGX-110 in Patients with Relapsed/Refractory CD70-Positive T-Cell Lymphomas -
Breda, The Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: AR...Read more
Hybrigenics acquires the genomic activities of Imaxio Pradeyrol Development invests EUR 1.3 million in Hybrigenics - Paris, 11 October 2013 – Hybrigenics (ALHYG), a bio-pharmaceutical company lis...Read more
LSP exits BMEYE to Edwards Lifesciences - LSP is proud to announce that it has sold its portfolio company BMEYE to Edwards...Read more
Hybrigenics starts Phase II clinical trial of inecalcitol in chronic lymphocytic leukemia - Paris, 11 September 2012 – Hybrigenics (ALHYG), a bio-pharmaceutical company l...Read more
LSP’s portfolio company arGEN-X raises targeted EUR 40 million in successful IPO on Euronext -
Amsterdam, the Netherlands, 10 July 2014. It is with great pleasure that toda...Read more
LSP leads a EUR 4.4 million Series A investment in Mint Solutions -
Amsterdam, the Netherlands, 8 July 2014. LSP (Life Sciences Partners), a lead...Read more
Hybrigenics first half 2013 revenues: robust 12% growth - Paris, 11 July 2013 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed...Read more
Atlas participates in £1.5m Grant Funding Award -
Simultaneous Detection of Infection and Antibiotic Resistance
Bath, ...Read more
PMV and LSP enter into strategic partnership in life sciences -
PMV and LSP enter into strategic partnership in life sciences
Brus...Read more
Hybrigenics’ inecalcitol gets Orphan Drug designation for the treatment of Acute Myeloid Leukemia in the United States -
Hybrigenics’ American clinical expenses eligible to US Orphan Drug tax cred...Read more
LSP leads a USD 27.2 million Series B investment in Rotation Medical -
Amsterdam, the Netherlands, 10 July 2014. LSP (Life Sciences Partners), a lea...Read more
Prosensa Completes Enrollment in Natural History Study of Duchenne Muscular Dystrophy -
Leiden, The Netherlands, June 25, 2014 - Prosensa Holding N.V. (NASDAQ: RNA),...Read more
Celladon Corporation Announces New Clinical Development Initiatives for MYDICAR(R) -
SAN DIEGO, July 7, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN...Read more
Mendor raises € 6,5 Million growth financing -
Espoo, Finland - Mendor, a leading diabetes technology company, is pleased to...Read more
arGEN-X raises €40 million in successful Initial Public Offering on Euronext Brussels -
Breda, the Netherlands / Ghent, Belgium, 8 July 2014 – arGEN-X N.V. (“arG...Read more
arGEN-X and The Leukemia & Lymphoma Society Partner on the Development of ARGX-110 for the Treatment of Waldenström’s Macroglobulinemia -
10 June 2014
Breda, the Netherlands / Ghent, Belgium and White Pla...Read more
Nexstim Selected as a 2014 Red Herring Top 100 Europe -
The Only Medical Device Company Awarded
Helsinki, Finland (April 9...Read more
CUPID 2 Results Expected in April 2015 -
SAN DIEGO, March 4, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLD...Read more
Hybrigenics’ inecalcitol shows promising potential in Acute Myeloid Leukemia -
Preclinical results are presented today at the 12th International Congress on...Read more
Curetis Prepares Launch of Second Unyvero™ Application -
Final clinical performance evaluation study for Unyvero™ i60 ITI applicatio...Read more
Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR(R), Novel, First-in-Class Therapy in Development to Treat Heart Failure -
MYDICAR is First Gene Therapy Reported to Receive Breakthrough Designation Fr...Read more
AbCheck Antibody Discovery Deal with Pierre Fabre -
Plzen, Czech Republic; April 2nd, 2014: AbCheck s.r.o., the multi antibody di...Read more
ARGEN-X USES ITS SIMPLE ANTIBODY™ PLATFORM TO IDENTIFY FOUR ‘HOTSPOTS’ ON MET AS TARGETS FOR ITS THERAPEUTIC ANTIBODY PROGRAM -
New findings to be presented at the American Association for Cancer Research ...Read more
Hybrigenics launches Helixio, its new branch dedicated to genomic services -
Paris, 03 April 2014 – Hybrigenics (ALHYG), a bio-pharmaceutical group list...Read more
LSP proud sponsor of the Mediscience Awards 2014 -
Voting Deadline: May 9th
Shortlist announced: May 22nd
...Read more
Achmea en LSP lanceren het LSP-Health Economics Fund voor innovatie in de zorg - Zeist / Amsterdam, 10 februari 2012 – Verzekeraar Achmea en investeringsmaatsc...Read more
arGEN-X Reports Preclinical Data on ARGX-110 in Chronic Myelogenous Leukemia Model -
Data to be presented at ASH demonstrate potential of ARGX-110 in reversing re...Read more
Kiadis Pharma Presents Positive Data from a Pre-specified Interim Analysis of the Phase II Clinical Program with its Lead Product ATIR™ -
~ Data confirms the potential of ATIR™ in partially matched hematopoietic s...Read more
Curetis Presents New Clinical Validation Data on its Unyvero™ P50 Pneumonia / LRT Application - - Clinical studies from U.S. and Switzerland confirm previous performance data
...Read more
Hybrigenics : green light for two European patents protecting new oral formulations of inecalcitol - Hybrigenics obtains patent protection until 2031 for innovative oral formulation...Read more
Curetis Completes Enrollment for its EU Trial As Planned - Prospective multi-center trial enrolls 800 patient samples in 7 months
Holzge...Read more
Hybrigenics’ patent estate of inhibitors of ubiquitin-specific proteases is expanding -
•Hybrigenics’ patent on its fourth chemical family of inhibitors of ubiqu...Read more
Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy -
Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) -- LEIDEN, The Nether...Read more
Curetis Initiates Prospective Multicenter Unyvero™ Study in Europe - - Study to demonstrate added value of Unyvero™ P50 pneumonia application in cl...Read more
Pronota’s Risk Stratification Test Breaks New Ground in the Early Detection of Pre-term Pre-eclampsia Cases in SCOPE Consortium Study - Ghent, Belgium, July 9, 2012. Pronota NV, a company dedicated to the development...Read more
4-Antibody AG and Evotec AG Form Strategic Collaboration - 4-Antibody and Evotec launch a new high-content screening platform for early ant...Read more
IlluminOss Medical Names Dirk Kuyper as Chief Executive Officer - New CEO Hired to Initiate Commercial Activities in Europe for its Photodynamic B...Read more
Curetis Initiates Clinical CE Performance Evaluation of Unyvero P55 Pneumonia Application -
Clinical study to test more than 400 patient samples
Follows succ...Read more
Probiodrug announces enrolment of first patient in Phase 2 Study of novel Treatment for Alzheimer’s disease -
First patient enrolled at leading Alzheimer Center in Amsterdam
HA...Read more
Major strategic agreement between Incyte and Agenus -
Through the attached link we are happy to inform you about a major strategic ...Read more
LSP’s Clemens Van Blitterswijk receives the prestigious Huibregtsen Prize for 2015 -
Amsterdam, the Netherlands - 7th October 2015 - Clemens van Blitterswijk, par...Read more
Affimed raises EUR 15.5 million in a Series D financing round - Heidelberg, Germany; October 8, 2012: Affimed Therapeutics AG, the therapeutic T...Read more
Biotech Update 2015 – A Sunny Afternoon Discussing Stroke, Sleep and “Immorbidity” -
Amsterdam, July 8, 2015. This year’s Biotech Update seminar, organized by L...Read more
LSP's portfolio company Kreatech sold to Leica - It is with great pleasure that LSP – the specialist European healthcare invest...Read more
TiGenix obtains national reimbursement in the Netherlands for breakthrough cartilage therapy ChondroCelect® - Leuven (BELGIUM) – June 8, 2012 – TiGenix (NYSE Euronext: TIG) announced tod...Read more
Celladon and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference" - -Analysis of Recurrent Heart Failure Hospitalizations in Presence of Informative...Read more
Merus reaches pivotal milestone in bispecific antibody collaboration with ONO PHARMACEUTICAL CO., LTD. -
- Successful product lead identification underscores the strength of Merus’...Read more
LSP’s steady hand -
Published in BioCentury, March 31, 2014
When LSP-Life Sciences Partners ...Read more
Zealand Pharma announces pipeline update - Copenhagen, 2013-03-08 08:28 CET (GLOBE NEWSWIRE) --
─ First European sales...Read more
arGEN-X advances a third therapeutic antibody program into preclinical development -
ARGX-111 IS AN ANTI-C-MET ANTIBODY WITH BROAD APPLICABILITY IN CANCER Rotterd...Read more
Affimed N.V. Announces Pricing of Public Offering of Common Stock -
Heidelberg, Germany, May 6, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical-st...Read more
Curetis Launches Unyvero™ i60 Implant and Tissue Infection Cartridge in Europe -
• Successful completion of CE performance evaluation study covering more th...Read more
TB, HIV and Malaria Vaccine Research Gets Major Boost $2.9 million Grant to Advance Chimpanzee Adenovirus Platform - Rockville, MD, US, Oxford, UK and Basel, Switzerland – 7 May 2013 – Aeras, a...Read more
Celladon Corporation is a Finalist for the 2013 Red Herring Top 100 North America Award - San Diego, California, May 7, 2013/PRNewswire/ -- Celladon Corporation, a biopha...Read more
Celladon Corporation Completes Second Close of Recent Venture Financing - -MPM Capital and LSP Life Sciences Partners join existing Celladon investment sy...Read more
LSP haalt Eur 112 mln op voor Health Economics Fund, ver boven target -
Amsterdam 7 Maart 2014. LSP haalt 112 mln euro op voor zijn Health Economics ...Read more
Kreatech signs supply agreement with lung cancer mutation consortium -
Kreatech to supply REPEAT-FREE™ DNA FISH probes for U.S. National Lung Stud...Read more
Merus Further Expands R&D Capacity - Company Contracts R&D Service Provider FairJourney Biologics
Utrecht, The Net...Read more
Merus Achieves Milestone with Novartis Option Fund - Company Reaches Milestone in Biclonics™ Program Partnered with Novartis
Utr...Read more
Larry Bell, MD Joins Prosensa as Head of Global Regulatory Affairs - Leiden, The Netherlands – 7 February 2013 – Prosensa Therapeutics, the Dutch...Read more
Celladon Corporation Conducts Initial Scale Up of Manufacturing Process for MYDICAR to Commercial Scale -
2,000L Demonstration Batch Completed at Lonza, Houston Facility
SAN ...Read more
Merus Selects Clinical Candidate for the Treatment of Acute Myeloid Leukemia (AML) - Utrecht, The Netherlands, January 7, 2013 – Merus B.V., a biopharmaceutical co...Read more
arGEN-X initiates Phase Ib study of ARGX-110 in cancer - Breda, the Netherlands, and Ghent, Belgium, January 7 2013 – arGEN-X, a biopha...Read more
arGEN-X expands its therapeutic antibody alliance with Shire - New discovery program initiated within 12 months of collaboration start
Breda...Read more
arGEN-X announces grant of broad US patent covering its SIMPLE Antibody™ platform - Breda, the Netherlands, and Ghent, Belgium, December 6, 2012 – arGEN-X, a biop...Read more
Curetis AG Initiates Clinical Trial in the U.S. Towards FDA Clearance - Prospective Multi-Center Trial to Enroll Over 2,000 Clinical Samples
Holzgerl...Read more
ARGEN-X ENTERS LONG-TERM STRATEGIC ALLIANCE WITH SHIRE PHARMACEUTICALS IN THERAPEUTIC ANTIBODIES -
SIGNIFICANTLY EXPANDED RELATIONSHIP CREATED ON BACK OF COLLABORATION SUCCESS
...Read more
Pronota is to receive patent on biomarker for diagnosing renal failure in the US despite Prometheus -
GHENT, BELGIUM, June 6, 2013 – The United States Patent and Trade Office (U...Read more
World first, as patient receives an implanted pump system to manage pleural effusions -
Swiss company’s innovative technology enables the automated management of e...Read more
International Consortium Awarded €6M to Validate Pre-Eclampsia Early Detection Tests - Cork, Ireland and Ghent, Belgium – 5 November 2012 – The European Union has ...Read more
Prosensa Wins Scrip 'Biotech Company of the Year' 2014 Award -
Leiden, The Netherlands, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Prosensa Holdin...Read more
LSP’s portfolio company Nexstim Plc successfully completes its IPO raising EUR 15.3 mln -
Amsterdam, the Netherlands, 4 November 2014. LSP (Life Sciences Partners), a ...Read more
arGEN-X and de Duve Institute/UCL to collaborate on novel immunomodulation therapy in cancer - 4 November 2013
Breda, The Netherlands / Ghent, Belgium – arGEN-X today ann...Read more
arGEN-X raises EUR 5 million from PMV in extension of EUR 32.5 million series B - Funds to advance ARGX-113, a novel antibody fragment approach to promote degrada...Read more
RuiYi (formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a Novel anti-IL-6 Antibody - Initial Development Strategy for Highly Potent Antibody Will be Focused on China...Read more
Setting the new standard in decentralised molecular diagnostics -
Bath, UK, 1 May 2015. Atlas Genetics Ltd (“Atlas” or the “Company”), ...Read more
Merus starts Phase I/II clinical trial for MCLA-128, an ADCC-enhanced bispecific antibody for solid tumors -
- First patient dosed in trial with potent bispecific antibody overcoming res...Read more
Probiodrug AG Raises Additional EUR15 Million to Advance Its Clinical Program - HALLE/SAALE, Germany, Jan. 4 2012 - Probiodrug AG today announced it has secured...Read more
LSP invests in Xeltis, a leading regenerative medicine company -
Amsterdam, the Netherlands, December 2, 2014. LSP (Life Sciences Partners), a...Read more
Probiodrug Publishes Further Evidence Correlating Glutaminyl Cyclase (QC) with Alzheimer’s Disease Pathogenesis and Cognitive Decline - HALLE/SAALE, Germany--(BUSINESS WIRE)-- Probiodrug AG (Probiodrug) and researche...Read more
LSP’s portfolio company Celladon listed on NASDAQ -
“It is with great pleasure that today; LSP – the specialist European heal...Read more
Lonza and Celladon Corporation Establish a Strategic Commercial Manufacturing Collaboration for MYDICAR(R) -
Agreement enhances existing relationship between Celladon and Lonza ...Read more
arGEN-X Submits Investigational New Drug Application to Evaluate ARGX-110 in Waldenström’s Macroglobulinemia -
Breda, The Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: AR...Read more
LSP's portfolio company Activaero sold to Vectura -
Amsterdam/Munich, March 13, 2014
We are happy to inform you that V...Read more
Merus Secures €31 Million in Series B Round Extension - - Investment brings Series B to a total of €47.6 million
- Johnson & Johnson ...Read more
Kiadis Pharma announces it raised an additional € 2.0 million via exercise of the Over-Allotment Option and the end of the stabilisation period in relation to its initial public offering -
Amsterdam, the Netherlands, July 31, 2015 – Kiadis Pharma N.V. (“Kiadis ...Read more
LSP company Kiadis Pharma listed on euronext through IPO -
A PDF version of Kiadis Pharmas' press release can be found here.
...Read more
LSP’s portfolio company Prosensa successfully listed on the Nasdaq - It is with great pleasure that today, LSP – the specialist European healthcare...Read more
Prosensa Announces Regulatory Path Forward for Drisapersen as a Potential Treatment for DMD -
Plans to Submit a New Drug Application to the FDA this Year; Dialogue with EM...Read more
arGEN-X to present results of Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced cancer at ASCO -
Breda, The Netherlands / Ghent, Belgium, 29 May 2014 – arGEN-X will present...Read more
Lonza and Celladon Announce Manufacturing Agreement for MYDICAR® - Agreement will support future clinical trials of Celladon's product candidate MY...Read more
Prosensa Provides Update on Drisapersen -
Re-dosing plans are underway and 96-week data from an open-label extension st...Read more
Hybrigenics successfully raised €6.1 million -
These funds will finance two new clinical Phase II studies of inecalcitol in ...Read more
Inspiring BioCapital Conference -
On March 27th, the prestigious hotel The Grand in Amsterdam set the stage for...Read more
Hybrigenics 2014 revenues and cash -
Scientific services turnover up 3%
Total operating revenues down 3%...Read more
Atlas Genetics completes $20m Series C fundraising -
Funds to accelerate global launch of Atlas io® molecular testing system
...Read more
Affimed Added to Russell 2000® Index -
Heidelberg, Germany, June 30, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical ...Read more
Prosensa holding B.V. prices initial public offering -
Leiden, the Netherlands—June 27, 2013—Prosensa Holding B.V. (“Prosensa...Read more
Hybrigenics acquires Dualsystems Biotech’s yeast two-hybrid (Y2H) activities - Hybrigenics Services will significantly strengthen its worldwide leadership as t...Read more
Merus appoints Mark Iwicki as President of the Supervisory Board -
Utrecht, The Netherlands, June 1, 2015 -- Merus B.V., a leader in developing ...Read more
Rudy Dekeyser and Clemens van Blitterswijk join LSP - [ NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA ]
Amsterdam, February ...Read more
Iris Sample Processing, a division of IRIS International and KREATECH Diagnostics sign distribution agreement for novel automated FISH sample preparation in Europe and North America - Amsterdam, March 1, 2012
Iris Sample Processing, a division of IRIS Internati...Read more
TEAM
Martijn Kleijwegt founded LSP in 1998 and is currently a Managing Partner...Read more
Mark Wegter joined LSP in 1998 and is currently a Managing Partner and co-own...Read more
Dr René Kuijten joined LSP in 2001 and is Managing Partner and co-own...Read more
Joachim (JR) Rothe, PhD, joined LSP in 2002 and is a Managing Partner and...Read more
John de Koning, PhD, joined LSP in 2006 and is a Partner of the firm. His pri...Read more
Geraldine O’Keeffe joined LSP in 2008. She became a Partner of the firm in ...Read more
Fouad Azzam, PhD, MBA, joined LSP in 2007. He became a Partner of the firm in...Read more
Jörg Neermann, PhD, joined LSP in 2007 as Partner. Jörg’s prime focus a...Read more
Anne Portwich, PhD, has been with LSP since 2001. She is a Partner in LSP’s...Read more
Rudy Dekeyser, PhD, joined LSP in 2012 and became Managing Partner of LSP’s...Read more
Professor Clemens van Blitterswijk, PhD, joined LSP in 2012. He became a Part...Read more
Drew Burdon, PhD, MBA, joined LSP in 2019 as an Investment Manager. Drew’s ...Read more
Bruno Holthof is the Chief Executive Officer (CEO) of Oxford University Hospi...Read more
Vincent Brichard, MD, PhD, MBA, joined LSP in 2016 as a Venture Partner. He w...Read more
Felice Verduyn-van Weegen joined LSP in 2015 as Associate and became an I...Read more
Edwin van den Broek joined LSP in December 2015 as a senior equity trader and...Read more
Karin Kleinhans, PhD joined LSP in 2015 as Associate and became an Investment...Read more
Arno de Wilde joined LSP in 2019 as an analyst. He is part of the LSP investm...Read more
Anna Bellmunt, PhD, joined LSP as an Analyst in 2020. She is part of the LSP ...Read more
Isabel Bahm, PhD, joined LSP in 2018 as Analyst. Isabel provides in-depth ana...Read more
Sonia Hallen, PhD, joined LSP in 2019. She is part of the LSP investment team...Read more
Hans Clevers MD PhD, has been a Venture Partner with LSP since 2001, except d...Read more
Pauline Bieringa is the Chairman of the NYSE Euronext listed LSP Life Science...Read more
Professor Dr. Anton Pijpers DVM PhD is the Chairman of the Supervisory Board/...Read more
André Olijslager is the Chairman of the Advisory Committee of the LSP Health...Read more
Maarten Scholten is the Chairman of the Supervisory Board of LSP Advisory. Un...Read more
Douwe Breimer PhD has been the former Chairman of the Supervisory Board of LS...Read more
Merijn Klaassen RC CAIA FRM joined LSP in early 2008 as Chief Financial Offic...Read more
Koen Sintnicolaas joined LSP in 2016 as a Business Controller. Within LSP he ...Read more
Bas Vaessen joined LSP as General Counsel in 2008. His prime focus and respon...Read more
Erika Boot joined LSP as Legal Counsel in 2009. With a background in civil an...Read more
Gisela Wolf joined LSP as Legal and Compliance Manager in 2018. Her prime...Read more
Edie de Kwaasteniet joined LSP as Tax Counsel in 2019. Within LSP she is resp...Read more
Hannie Wiersema joined LSP at our Amsterdam office in February 2006 as financ...Read more
Suzanne Dwinger is office manager and personal assistant at LSP within the Am...Read more
Manuela Jaeger joined LSP in October 2019 as an office manager and executive ...Read more
HOME -
Today, society faces many challenges. Too many people suffer from diseases that are not diagnosed accurately, not well treated, not cured satisfact...Read more
TRACK RECORD -
Over the past 30 years, we have provided start-up and growth capital to more than 200 companies. Operating at the forefront of medical innovation, ...Read more
TEAM -
Our successful 30 year investment history is based on our conviction that seeking, helping and supporting the smartest people with the best ideas r...Read more
FUNDS -
Our activities as a dedicated private equity healthcare investor date back to the late 1980s. At that time, providing start-up and growth capital t...Read more
PORTFOLIO -
Our activities as a dedicated private equity healthcare investor date back to the late 1980s. At that time, providing start-up and growth capital t...Read more
IMPACT -
The companies we invest in all help to address some of the medical needs that are not met by current products or technologies. In other words, they...Read more
Translating academic careers into industry healthcare professions -
Though academic institutions have contributed enormously to the remarkable gr...Read more
GTX medical Granted FDA Breakthrough Device Designation for Go-2 Targeted Epidural Spinal Stimulation (TESS) System -
Eindhoven, NL and Lausanne, CH: June 9, 2020 - GTX medical (GTX), today annou...Read more
argenx announces positive topline Phase 3 ADAPT Trial Results -
May 26, 2020 - Breda, the Netherlands / Ghent, Belgium
Trial ...Read more
argenx announces full exercise of underwriters’ option to purchase additional ADSs -
May 29, 2020 - Breda, the Netherlands / Ghent, Belgium - argenx (Euro...Read more
Zealand Pharma announces FDA acceptance of New Drug Application for the dasiglucagon HypoPal® rescue pen for treatment of severe hypoglycemia -
The dasiglucagon HypoPal® rescue pen New Drug Application represents a m...Read more
LSP portfolio company Orphazyme announced that the company has received Fast Track Designation from FDA -
Orphazyme’s arimoclomol receives US Fast Track Designation in Amyotrophic L...Read more
First truly biocompatible MIGS implant from iSTAR Medical shows consistently outstanding efficacy in patients with glaucoma -
Two-year final results from STAR-I trial and initial data from STAR-II Europe...Read more
Immunic, Inc. Announces Pricing of $15 Million Financing -
NEW YORK, April 23, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a c...Read more
Immunic Inc. has demonstrated preclinical activity against SARS-CoV2 -
NEW YORK, April 21, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a c...Read more
FoRx Therapeutics AG Raises EUR 10 Million Seed Round -
First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress...Read more
COVID-19 – Perspective from a Biotech Investor Part 2 -
by Geraldine O'Keeffe and Mark Wegter
Amsterdam, April 23, 202...Read more
Binx aims to capture a milestone in STI testing technology -
Three months ago Binx Health, a Boston-based biotech firm founded in 2005, st...Read more
Simplify Medical Completes PMA Submission for 1-Level Simplify Disc IDE Study -
SUNNYVALE, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Simplify Medical Pty Lt...Read more
AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI -
€23m (US$25.5m) equity provided mainly by US-based Cowen Healthcare Inv...Read more
Zealand Pharma submits New Drug Application -
Zealand Pharma submits New Drug Application to the U.S. Food and Drug Adminis...Read more
COVID-19 – Perspective from a Biotech Investor -
by Geraldine O’Keeffe and Mark Wegter
The purpose of this memo i...Read more
LSP’s portfolio company eTheRNA launches SARS-CoV-2 mRNA vaccine program for COVID-19 -
eTheRNA Launches an International Consortium and Starts Development of Cross-...Read more
LSP closes largest ever European life sciences fund at $600 million -
Amsterdam, Munich, Boston, 10 March 2020
LSP, the leading life s...Read more
Orphazyme completes offering of 7,032,937 shares in a directed issue and private placement -
Copenhagen, Denmark, February 7, 2020 – Orphazyme A/S (ORPHA.CO), a biophar...Read more
Atlantic Therapeutics Announces FDA Clearance for Over-the-Counter Use of INNOVO -
February 06, 2020
GALWAY, Ireland--Atlantic Therapeutics, a global...Read more
LSP portfolio company binx announces launch of its pre-order program for the world's first FDA-cleared, rapid molecular point-of-care instrument -
binx offers first FDA 510(k) cleared molecular point-of-care solution for tes...Read more
LSP 5 portfolio company ImCheck Therapeutics raises € 48 million ($ 53 million) to drive clinical program for cancer and autoimmune diseases -
Amsterdam, The Netherlands, December 04, 2019 – LSP, the leading European l...Read more
LSP's portfolio company Arvelle announces FDA approval of anti-epileptic drug cenobamate -
Amsterdam, 26 November 2019 - LSP's portfolio company Arvelle Therapeutic...Read more
LSP’s portfolio company GTX medical and NeuroRecovery Technologies Inc. merge to create leading neurostimulation company for spinal cord injury -
Eindhoven, NL and Lausanne, CH; Los Angeles, USA; October 22, 2019 – GTX m...Read more
LSP’s portfolio company GTX medical and NeuroRecovery Technologies Inc. merge to create leading neurostimulation company for spinal cord injury -
Eindhoven, NL and Lausanne, CH; Los Angeles, USA; October 22, 2019 – GTX m...Read more
Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions -
Tumor shrinkage observed in three patients harboring NRG1 fusions (two pancre...Read more
LSP portfolio company ARGENX successfully raises $484 million in a public offering -
LSP portfolio company ARGENX successfully raises $484 million in a public off...Read more
LSP portfolio company Merus successfully raises $68.9 million in a public offering -
LSP portfolio company Merus successfully raises $68.9 million in a public off...Read more
SCOPE 'Dossier Private equity' -
In de bijzondere seminareditie van Mgmt. SCOPE 'Dossier Private equity...Read more
Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist -
SAN DIEGO, Sept. 18, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a cli...Read more
LSP portfolio company Pharvaris B.V. announced a $66 mln Series B round -
Pharvaris Announces $66 Million Series B Financing to Advance the Clinical De...Read more
Immunic, Inc.'s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range -
– Unblinded Data Review Committee Recommended Continuation of the Lowes...Read more
LSP joins as new investor in Nkarta Therapeutics in it's series B finanancing -
Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Mult...Read more
LSP leads EUR 40 million Series C funding in iSTAR Medical -
Amsterdam, the Netherlands — 5 September 2019: LSP, one of Europe’s leadi...Read more
Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusion -
Kuros to conduct Phase 2a trial in spinal fusion, comparing Fibrin-PTH to...Read more
LSP portfolio company Binx Health to receive 510(k) marketing authorization for its io- system -
binx io enables first-ever “test-and-treat” paradigm with sample to answe...Read more
Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Primary Sclerosing Cholangitis -
– Study Being Conducted in Collaboration with Investigators at Arizona Stat...Read more
Immunic AG Awarded Research Grant by German Federal Ministry of Education and Research in Support of the InnoMuNiCH Project -
SAN DIEGO, Aug. 1, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clini...Read more
ImCheck Therapeutics Awarded €2 Million from Bpifrance to Advance its First-in-Class Immunotherapy Program into the Clinic -
Bpifrance views ImCheck’s projects as unique and well-positioned
Mar...Read more
LSP leads €67m [$75m] Series A financing in Alizé Pharma 3 -
Significantly oversubscribed financing round with an LSP-led internationa...Read more
Imcyse gives hope to patients with diabetes and MS -
De Tijd - Biotech bedrijf Imcyse biedt hoop aan patiënten met diabetes en MS...Read more
Curetis Files for U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens -
Final LRT BAL panel demonstrates overall weighted average sensitivity of ...Read more
Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC) -
US Food and Drug Administration (FDA) agrees to Orphazyme’s plan to fi...Read more
ImCheck Therapeutics appoints Paul Frohna MD, PhD, PharmD, as Chief Medical Officer -
Paul Frohna brings over 15 years of experience in translational medicine and ...Read more
Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in Amyotrophic Lateral Sclerosis -
Headline results from full analysis expected in H1 2021
Cope...Read more
Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer -
SAN DIEGO, July 16, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clin...Read more
LSP in the FD – ‘Biotechbedrijf AM Pharma haalt €116 mln op’ -
Today in the Financieele Dagblad 'Biotech company AM Pharma raising €11...Read more
LSP leads €116m [$133m] financing in AM-Pharma to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury -
Financing led by LSP and co-led by Andera Partners, with participation of...Read more
MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology -
HALLE (SAALE) and PLANEGG/MUNICH, Germany, 8 July 2019: Vivoryon Therapeutics...Read more
Immunic, Inc. to Present Previously Unpublished Data Regarding Lead Program, IMU-838, at the GI Inflammatory Diseases Summit in Boston -
SAN DIEGO, June 24, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clin...Read more
LSP's portfolio company Nouscom demonstrates Preclinical Proof of Concept for Personalized Cancer Neoantigen Vaccine in combination with Immune Checkpoint Blockade to Eradicate Large Tumors -
Article published in Nature Communications
BASEL, Switzerland – 19...Read more
LSP leads € 28 million Series B financing in Imcyse -
Imcyse raises a total of € 35 million in equity and grants and will use pro...Read more
Merus Announces Financial Results for the First Quarter 2019 and Provides Business Update -
UTRECHT, The Netherlands, May 30, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq...Read more
argenx announces publication of efgartigimod Phase 2 myasthenia gravis trial results in Neurology -
Breda, the Netherlands / Ghent, Belgium, May 28, 2019 – argenx (Euronext &...Read more
Kiadis Submits Response to the European Medicines Agency's Day 180 Second List of Outstanding Issues -
Amsterdam, The Netherlands, May 22, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma...Read more
argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day -
Expands pipeline with ARGX-117 and ARGX-118; two new pipeline candidates ...Read more
LSP leads $38.5 Million Series B Financing in DNA Script -
Oversubscribed round led by LSP will fund accelerated product development and...Read more
Okairos winner of the Swiss Biotech Success Stories Awards 2018/19 -
Basel, Switzerland, May 7, 2019 – LSP is pleased to announce that Okairos h...Read more
Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors -
UTRECHT, Netherlands, May 09, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq...Read more
argenx reports first quarter 2019 financial results and provide business update -
Breda, the Netherlands / Ghent, Belgium, May 9, 2019 - argenx (Euronext & Na...Read more
LSP’s portfolio company Binx Health Receives CE Mark for Rapid Chlamydia and Gonorrhea Test for Mass Markets -
Multiplex Test Panel for binx io® Point-of-Care Platform
Positioned to R...Read more
Immunic, Inc. Appoints Industry Veteran Tamara A. Seymour as Interim Chief Financial Officer -
SAN DIEGO, April 29, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage ...Read more
The French Région Sud and the European Union provide grant funding to Imcheck Therapeutics and its development of a new generation of cancer treatments -
Through a 717 K€ grant co-financed by the Région Sud and the European Unio...Read more
LSP Life Sciences Fund Performing strongly and ending Q1 2019 up +17.5% -
For more insight into our returns and investment strategy please read our jus...Read more
Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases -
Developing Oral Therapies with Best-in-Class Potential
Lead Program...Read more
Upcoming Event: Biotech update 2019 -
Biotech Update 2019
Wednesday 26th June, 2019
Kasteel De Wittenburg i...Read more
Probiodrug raises EUR 8.2 million from investors in successful private placement of new shares -
Capital increase of its share capital by issuing 4,093,367 new shares at ...Read more
Merus Announces Financial Results for the Full Year 2018 and Provides Business Update -
Multiple Updates from Biclonics® Clinical Trials Expected in 2019
...Read more
Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019 -
CD137 and PD-L1 bispecific antibody with context-dependent T cell activation
...Read more
Curetis and Menarini Diagnostics Enter into Strategic Pan-European Exclusive Partnership for the Distribution of Curetis’ Unyvero -
Curetis and Menarini Diagnostics Enter into Strategic Pan-European Exclusive ...Read more
Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases -
Collaboration furthers Alexion’s complement leadership with expansion i...Read more
Probiodrug and Alzheimer’s Disease Cooperative Study (ADCS) Receive 15 Million USD National Institutes of Health (NIH) Grant for U.S. Phase 2b Core Program for PQ912 -
HALLE (SAALE), Germany and San Diego, CA – USA, 20 March 2019 – Probiodru...Read more
EMA making its first public appearance at our conference -
The timing was perfect – the EMA would complete its move to Amsterdam in Ma...Read more
Amarin – a story close to our hearts, Keynote speaker at BioCapital -
Keynote speaker CEO John Thero telling this remarkable story on our BioCapita...Read more
argenx to receive first clinical milestone payment for product candidate developed under option agreement with AbbVie -
Initiation of first-in-human clinical trial with antibody product candida...Read more
LSP co-leads $50 million Series A financing in SNIPR BIOME -
Copenhagen, 11 March 2019 - SNIPR BIOME, a leading CRISPR and microbiome priv...Read more
argenx reports fourth quarter business update and full year 2018 financial results -
Breda, the Netherlands / Ghent, Belgium - February 28, 2019 – argenx (Euron...Read more
Immunic Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of IMU-838, an Oral Therapy for Patients with Relapsing-Remitting Multiple Sclerosis -
Planegg-Martinsried, Germany, February 26, 2019 – Immunic AG (Immunic), a p...Read more
LSP leads $180 million Series A Financing in Newly-Formed Arvelle Therapeutics -
LSP leads one of the largest initial financings for a European biotech compan...Read more
Kuros Biosciences signs agreement to supply SeaSpine with bone graft incorporating Kuros’s advanced submicron surface technology -
Global partner to market an advanced bone graft supplied by Kuros
A...Read more
LSP's portfolio company GTX Medical on “Dokters van Morgen” -
Dutch TV program 'Dokters van Morgen' reporting on new revolutionary ...Read more
argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology -
argenx gains access to ENHANZE® subcutaneous delivery technology for up ...Read more
Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC) -
Primary endpoint shows 74% reduction in disease progression after 12 mont...Read more
LSP leads €28 million Series B financing in Atlantic Therapeutics -
Amsterdam, the Netherlands, January 7, 2019 – LSP, one of Europe’s leadin...Read more
Merus Announces IND Clearance for MCLA-145 -
MCLA-145 is a full-length human bispecific antibody binding to PD-L1 and CD13...Read more
Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company -
Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Fo...Read more
Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Update -
Clinical milestones for four lead Biclonics® programs expected in 2019
C...Read more
Merus Announces Strategic Collaboration with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China -
Merus to retain all global rights outside of China
Betta Pharmaceuticals ...Read more
Merus Announces Global Settlement and End to All Patent Litigation with Regeneron Pharmaceuticals -
Merus and Regeneron to cross-license patents relating to certain antibody gen...Read more
Kuros ends transformational year with first MagnetOs sales, lead clinical program on track, and successful capital raise -
Successfully raised CHF 16.1 million from existing and new investors
...Read more
Kuros announces final result of capital increase – total gross proceeds of 16.1 million raised -
Schlieren (Zurich), Switzerland, December 13, 2018 – Kuros Biosciences (SIX...Read more
Kuros announces results of rights offering – capital increase will be implemented -
Schlieren (Zurich), Switzerland, December 12, 2018 – Kuros Biosciences (SIX...Read more
Aelin Therapeutics pursues new cancer drugs -
The young biotech spin-off gains momentum with a VLAIO grant and an investor ...Read more
Orphazyme expects to announce results of full data set for Niemann-Pick disease Type C (NPC) Phase II/III trial in Q1 2019 -
Copenhagen, December 10, 2018 – Orphazyme A/S, a biopharmaceutical company ...Read more
LSP co-leads $17 Million Series A financing in XyloCor Therapeutics to advance gene therapy in cardiovascular disease -
Novel gene therapy for patients with treatment-resistant angina who have ...Read more
LSP leads $28 million financing in Lumeon -
Amsterdam, the Netherlands, December 4, 2018 – LSP, one of Europe’s l...Read more
argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia -
Detailed Phase 2 ITP data show clear correlation between IgG reduction, p...Read more
argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110) -
Regulated information – Inside information
Collaboration to de...Read more
LSP wins Lifestars Award for EU investment firm of the year -
Celebrating success across life sciences
Amsterdam, The Netherland...Read more
Simplify Medical Completes Enrollment in U.S. IDE Pivotal Trial of Simplify® Disc for Two-Level Cervical Disc Replacement -
Sunnyvale, CA – November 14, 2018 – Simplify Medical Pty Ltd., maker of t...Read more
LSP raises record €750 million in 10 months for life sciences innovations -
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JA...Read more
Immunic enters into a global option and license agreement with Daiichi Sankyo -
Immunic AG gains exclusive, worldwide rights to promising drug development pr...Read more
Product of LSP’s portfolio company GTX medical restores walking in humans with spinal cord injury -
Amsterdam, The Netherlands, November 1, 2018 – LSP’s portfolio company GT...Read more
argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exposition -
Regulated information – Inside information
92% overall response ra...Read more
argenx reports third quarter 2018 financial results and provides business update -
Breda, the Netherlands / Ghent, Belgium, October 25, 2018 - argenx (Euronext...Read more
Orphazyme reports encouraging arimoclomol clinical trial top-line data in Niemann-Pick disease Type C (NPC) -
Arimoclomol was well-tolerated in patients with the rare disease NPC
...Read more
Merus Strengthens Team with Key Appointments -
Hui Liu, Ph.D., EVP, Chief Business Officer, appointed Head of Merus U.S.
...Read more
Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children -
The pediatric Phase 3 trial will enroll up to 40 children with Type 1 dia...Read more
argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia -
Favorable safety and tolerability consistent with efgartigimod clinical t...Read more
LSP leads $45 million Series D Financing in Endotronix -
Amsterdam, the Netherlands, September 17, 2018 – LSP, Europe’s leading li...Read more
argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis -
Breda, the Netherlands / Ghent, Belgium, September 6, 2018 - argenx (Euronex...Read more
Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets -
Affimed will receive $96 million upfront and committed funding and is eligibl...Read more
Merus Announces Formation of a Scientific Advisory Board -
- Key Oncology and Drug Development Professionals to Support Advancement of M...Read more
argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody -
Breda, the Netherlands/Ghent, Belgium, August 22, 2018 - argenx (Euronext & N...Read more
LSP co-leads $85 million (£65 million) Series B Financing in Artios Pharma -
LSP returns to support the former KuDOS team that successfully developed the ...Read more
argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris -
Rapid disease control observed in 4/6 patients
Strong PD effect cor...Read more
argenx receives second preclinical milestone payment under its development agreement with AbbVie -
Breda, the Netherlands/Ghent, Belgium, June 28, 2018 - argenx (Euronext & Na...Read more
Kuros Biosciences to present promising clinical case studies with MagnetOs at leading spine surgery conference -
Schlieren (Zurich), Switzerland, June 19, 2018 - Kuros Biosciences will this ...Read more
argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation -
- Subcutaneous formulation offers potential for increased patient convenience...Read more
Zealand Pharma achieves milestone in first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes -
Zealand Pharma achieves milestone in first Phase 3 trial with dasiglucagon fo...Read more
eTheRNA enrols first patient in high dose cohort of Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma -
Niel (Belgium), 24 May 2018 — eTheRNA immunotherapies, a clinical-stage com...Read more
Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors -
- IND Accepted in April by the U.S. FDA for MCLA-158 -
UTRECHT, The Ne...Read more
Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell -
UTRECHT, The Netherlands, May 15, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Na...Read more
De Telegraaf: gespreid in biotech en profiteren van overnames via LSP -
Lees de gehele column: gespreid in biotech en profiteren van overnames via LS...Read more
argenx reports first quarter 2018 financial results and provides business update -
Breda, the Netherlands / Ghent, Belgium, May 9, 2018 - argenx (Euronext ...Read more
Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017 -
Phase 2 combination trial in two metastatic breast cancer (MBC) populatio...Read more
Immunic reports start of enrollment into clinical Phase 2 study with IMU-838 in patients with ulcerative colitis -
First patient with ulcerative colitis entered the ‘CALDOSE-1’ trial w...Read more
Probiodrug Appoints Dr. Ulrich Dauer as Chief Executive Officer -
Dr. Ulrich Dauer to team up with Chief Development Officer, Dr. Inge Lues, ef...Read more
argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting -
Eight-week follow-up data show separation of clinical efficacy scores bet...Read more
argenx to receive third preclinical milestone payment from collaboration with LEO Pharma - Milestone associated with CTA approval for ARGX-112 -
Breda, the Netherlands/Ghent, Belgium, April 12, 2018 - argenx (Euronext & Na...Read more
Zealand and Roche Diabetes Care enter Phase 3 study collaboration for treatment of congenital hyperinsulinism with dasiglucagon -
Zealand has entered a collaboration agreement with Roche Diabetes Care to...Read more
argenx appoints Keith Woods as Chief Operating Officer -
Breda, the Netherlands / Ghent, Belgium, April 9, 2018 - argenx (Euronext & ...Read more
argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe -
Breda, the Netherlands / Ghent, Belgium, March 26, 2018 - argenx (Euronext &...Read more
Merus and the Vall d’Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applications in the Treatment of Cancer -
UTRECHT, The Netherlands, March 20, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasd...Read more
Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune Diseases -
UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasd...Read more
Merus’ Intellectual Property Portfolio Expands with Two New Patents -
Merus’ First U.S. Patent Covering MCLA-117 and Merus’ Spleen to Screen® ...Read more
Merus Announces $55.8 Million Private Placement Offering of Common Stock -
UTRECHT, The Netherlands, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasda...Read more
LSP invests in Simplify Medical to bring the company’s innovative cervical disc to the US Market -
Amsterdam, the Netherlands - 12 February 2018 - LSP announces its investment ...Read more
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten -
Oncode Institute combines 600 of the very best oncology researchers with a hi...Read more
LSP Life Sciences Fund makes 250% on Ablynx sale -
To read the full article click here.
...Read more
Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations -
Combination trial to evaluate MCLA-128 in HER2-positive and hormone receptor-...Read more
Merus and Simcere Announce Strategic Collaboration on Multiple Bispecific Antibodies -
UTRECHT, Netherlands and NANJING, China, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Me...Read more
BioCapital Europe 2018, organised by LSP -
BioCapital Europe 2018, an LSP (Life Sciences Partners) event, is delighted t...Read more
LSP reaches milestone: 10 years investing in listed Life Sciences Securities -
LSP Life Sciences Fund generates net return of 39% in 2017
Amsterd...Read more
FDA approves IND for Immunic Therapeutics’ IMU-838 to proceed with Phase 2 study in ulcerative colitis -
FDA has granted IND approval for Immunic’s oral investigational drug IM...Read more
Takeda to acquire LSP portfolio company TiGenix -
Takeda announces its intention to acquire TiGenix
Leuven (BELGIUM)...Read more
Merus Provides Clinical Updates for MCLA-117 and MCLA-158 Programs -
- IND submitted to U.S. FDA for MCLA-117 in AML -
- First CTA approval fo...Read more
Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron -
UTRECHT, The Netherlands, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasda...Read more
Kiadis CEO interviewed by the Dutch financial radio station BNR -
Good afternoon, As we continue to make significant operational progress at Ki...Read more
argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering -
Regulated information - Inside information
Breda, the Netherlan...Read more
Immunic Therapeutics Successfully Completes two Phase 1 Studies for IMU-838 -
Two phase 1 studies for IMU-838 in healthy volunteers have been completed...Read more
LSP Raises EUR 280 Million to Invest In Healthcare Innovation -
Largest fund in Europe dedicated to medical technology
Significant fundra...Read more
Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH -
Completed dose-escalation shows combination of AFM13 and pembrolizumab is wel...Read more
LSP leads EUR 27 mln Series A financing of new VIB start-up Aelin Therapeutics to exploit its proprietary Pept-in™ protein knockdown platform -
Leuven, Belgium – 11 December 2017 – Aelin Therapeutics, a privately held...Read more
argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting -
Workshop to be held on Monday, December 11th at 12:00 pm EST
Breda, the ...Read more
argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis -
Favorable tolerability profile consistent with Phase 1 data
ARGX-11...Read more
LSP Partner Clemens van Blitterswijk gives a Tedx on the future of regenerative medicine -
The video is now online via the following link
...Read more
LSP's portfolio company Affimed described -
To read the full article click here.
...Read more
Is a cure for cancer finally within reach? -
To read the full article click here
...Read more
Kuros Biosciences May Secure Equity Financing of up to CHF 30 million -
Schlieren (Zurich), Switzerland, November 22, 2017 - Kuros (SIX: KURN) announ...Read more
LSP’s portfolio company Orphazyme raises approximately €80 million in oversubscribed IPO -
Amsterdam, The Netherlands – 16 November 2017 – It is with great pleasure...Read more
LSP’s portfolio company Xeltis raises a substantial new round -
Amsterdam, the Netherlands, November 16, 2017 – LSP (Life Sciences Partners...Read more
argenx launches Phase I trial with subcutaneous formulation of ARGX-113 -
Subcutaneous formulation intended for chronic therapy setting
Octo...Read more
LSP portfolio company Nouscom raises € 42m Series B round -
Financing to advance its pipeline of neoantigen cancer based immunotherapies ...Read more
argenx reports third quarter 2017 financial results and provides business update -
October 26, 2017, Breda, the Netherlands / Ghent, Belgium argenx (Euronext Br...Read more
Ventaleon GmbH reports clear clinical progress and additions to the Supervisory Board -
- Last participant enters human challenge trial, data expected by year end 20...Read more
U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome -
Copenhagen, Denmark, October 24, 2017 - The U.S. Food and Drug Administration...Read more
Smith & Nephew acquires tissue regeneration technology for shoulder repair -
Amsterdam, the Netherlands, October 24, 2017 - Smith & Nephew plc (LSE:SN, NY...Read more
LSP portfolio company Imcheck Therapeutics obtains 1M€ from Bpifrance to contribute to the development of a novel therapeutic antibody in immuno-oncology -
First non-dilutive funding received by ImCheck
following its initial fu...Read more
argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis -
Non-regulated information
Breda, the Netherlands / Ghent, Belgium,...Read more
Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress -
UTRECHT, The Netherlands, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASD...Read more
Merus’ Intellectual Property Portfolio Expands with Two New Patents For its Biclonics® Technology -
UTRECHT, The Netherlands, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Merus (NASDAQ:MR...Read more
Kiadis Pharma receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation for ATIR101™ -
Amsterdam-Duivendrecht, The Netherlands, September 20, 2017 – Kiadis Pharma...Read more
argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia -
Top-line data from the study expected in second half of 2018 -
...Read more
BioCentury: LSP's Four of a Kind -
To read the full article click here
...Read more
Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million -
Omega and Fund+ broaden Immunic’s investor base and add an additional E...Read more
Kuros receives clearance for MagnetOs Putty for commercialization in the United States and files the product for CE marking in Europe -
Schlieren (Zurich), Switzerland, August 28, 2017 – Kuros Biosciences announ...Read more
argenx reports second quarter business update and half-year 2017 financial results -
Breda, the Netherlands / Ghent, Belgium, August 24, 2017 - argenx (Euronext ...Read more
argenx announces publication in Nature Medicine of preclinical data supporting the therapeutic potential of SIMPLE AntibodyTM ARGX-116 for the treatment of dyslipidemia -
- anti-ApoC3 antibody developed as part of research collaboration with Staten...Read more
U.S. Court of Appeals for the Federal Circuit affairms Merus’ inequitable conduct claim against Regeneron -
UTRECHT, The Netherlands, July 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasda...Read more
Kiadis Pharma proposes former Actelion COO Otto Schwarz as new Supervisory Board member -
Amsterdam-Duivendrecht, The Netherlands, July 26, 2017 – Kiadis Pharma N.V....Read more
LSP extends its portfolio in medical devices and invests in Simplify Medical -
Amsterdam, the Netherlands - 20 July 2017 - LSP (Life Sciences Partners) anno...Read more
Marco Groot blikt in het FD terug op zijn eerdere positieve aanbeveling op LSP -
Lees de gehele column: Actief beleggen loont
...Read more
Merus Announces First Quarter 2017 Financial Results and Mid-Year Operating Results -
Balance sheet strengthened with $120 million upfront payment and an $80 milli...Read more
eTheRNA advances in-vivo mRNA cancer immunotherapy into first oncology clinical studies -
TriMix-MEL (ECI-003), a rationally designed mRNA immunotherapy based on the u...Read more
argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein at Best of ASCO Asia 2017 (Singapore) -
Breda, the Netherlands / Ghent, Belgium, July 7, 2017 - argenx (Euronext & Na...Read more
Zealand initiates first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes -
First patients enrolled in a multinational Phase 3 clinical trial of dasi...Read more
BioCapital Europe 2018, organised by LSP -
BioCapital Europe 2018, organised by LSP (Life Sciences Partners) is delighte...Read more
argenx receives second preclinical milestone payment in collaboration with LEO Pharma -
Breda, the Netherlands / Ghent, Belgium, June 20, 2017 - argenx (Euronext & N...Read more
Zealand Pharma announces positive results from the Phase 2 trial of glepaglutide -
Glepaglutide meets primary endpoint in Phase 2 trial in patients with short b...Read more
argenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-cell lymphomas at the International Conference of Malignant Lymphoma (ICML) -
Breda, the Netherlands / Ghent, Belgium, June 14, 2017 - argenx (Euronext & N...Read more
LSP’s portfolio company Probiodrug reports positive results in Alzheimer Disease Patients -
Munich/Amsterdam – 13 June 2017 – LSP proudly announces that its port...Read more
Ventaleon GmbH Initiates Challenge Trial with Inhaled Flu Treatment Candidate -
Human challenge study to assess safety, tolerability and efficacy of inha...Read more
Zealand Pharma announces positive Phase 2a results with microdoses of dasiglucagon support use in a dual-hormone artificial pancreas system -
Dasiglucagon is a potential first-in-class glucagon analogue for pump use...Read more
argenx announces full exercise of underwriters' option to purchase additional ADSs -
Regulated information - inside information
Breda, the Netherlands ...Read more
LSP’s portfolio company argenx raises approximately $100 million with NASDAQ IPO -
Amsterdam, The Netherlands – 19 May 2017 – It is with great pleasure that...Read more
Merus Announces Promising Results from MCLA-128 Phase 1/2 Study in Metastatic Breast Cancer -
Results to be presented at the 2017 American Society of Clinical Oncology Ann...Read more
argenx announces size of initial public offering in the United States increased to 5 million ADSs -
Regulated information - inside information
Breda, the Netherlands ...Read more
LSP leads € 15M series A round of Cardiovascular start-up Cardior Pharmaceuticals -
Munich, Germany — May 11, 2017 — LSP (Life Sciences Partners), a leading ...Read more
LSP Portfolio Company Luxendo acquired by Bruker -
Successful exit after 1,5 years validates LSPs investment rationale
...Read more
argenx announces launch of proposed initial public offering in the United States -
Regulated information - inside information
Breda, the Netherlands ...Read more
argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis -
Top-line data from the study expected in first quarter of 2018
Bred...Read more
CORRECTING and REPLACING -- Merus Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Developments -
In a release issued April 28, 2017 by Merus N.V. (Nasdaq:MRUS) with the same ...Read more
LSP extends its portfolio in immuno-oncology and invests in the € 20 million Series A round of Imcheck Therapeutics -
Amsterdam, the Netherlands — May 3, 2017 — LSP (Life Sciences Partners), ...Read more
argenx reports first quarter 2017 financial results and provides business update -
Breda, the Netherlands/Ghent, Belgium, May 2, 2017 - argenx (Euronext Bruss...Read more
Kiadis Pharma announces filing of marketing authorization with the European Medicines Agency for ATIR101™ in blood cancers -
Amsterdam, The Netherlands, April 26, 2017 – Kiadis Pharma N.V. (“Kiadis ...Read more
Recent Data on Curetis’ Unyvero ITI Application Demonstrate its Clinical and Health Economic Benefits -
Several ECCMID 2017 presentations highlight advantages of rapid time to r...Read more
argenx announces results of Annual General Meeting 2017 -
Breda, the Netherlands / Ghent, Belgium, April 26, 2017 - argenx N.V. (Eurone...Read more
argenx files registration statement for a proposed public offering in the United States -
Breda, the Netherlands / Ghent, Belgium, April 24, 2017 - argenx N.V. (Eurone...Read more
Merus Announces Data from a Phase 1/2 Study of MCLA-128 to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting -
UTRECHT, The Netherlands, April 20, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASD...Read more
argenx receives first preclinical milestone payment in AbbVie collaboration -
Breda, the Netherlands/Ghent, Belgium - April 13, 2017 - argenx (Euronext Br...Read more
Marco Groot over LSP in het FD -
Amsterdam, April 11, 2017
Marco Groot over LSP in het FD
Lees de gehe...Read more
Kuros announces CEO succession -
Commercialization veteran and life science executive Dr. Ivan Cohen-Tanug...Read more
argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients -
Interim data expected by end of 2017
Breda, the Netherlands/Ghen...Read more
15th BioCapital Europe -
March 15, 2017 – The 15th BioCapital Europe Conference took place at the pr...Read more
LSP’s portfolio company Neuravi acquired by Codman Neuro -
Amsterdam, the Netherlands, April 10, 2017 – LSP (Life Sciences Partners), ...Read more
Last Patient Last Visit (LPLV) reached in the SAPHIR Study -
Last Patient Last Visit (LPLV) reached in the SAPHIR Study, a Phase 2 trial w...Read more
argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia -
Breda, the Netherlands / Ghent, Belgium, March 31, 2017 - argenx (Euronext B...Read more
argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases -
Differentiated antibody to address complement target
Represents l...Read more
Merus Named BioCapital Europe 2017 Company of the Year -
Award Recognizes Company’s Substantial Transformation and Breakthroughs Ove...Read more
argenx reports fourth quarter business update and full year 2016 financial results -
Breda, the Netherlands / Ghent, Belgium, March 15, 2017 - argenx (Euronex...Read more
LSP invests in Orphazyme as part of a EUR 14 million Series B extension to further expand clinical programmes -
Amsterdam, The Netherlands, March 15, 2017 - LSP portfolio company Orphazyme ...Read more
LSP takes part in Euronext Amsterdam gong ceremony -
BioCapital Europe, an LSP healthcare conference, will take place for the 15th...Read more
argenx announces that Staten Biotech exercised its option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia -
Anti-ApoC3 antibody developed as part of research collaboration on dyslip...Read more
argenx announces intention to conduct a registered public offering in the United States -
Breda, the Netherlands / Ghent, Belgium, March 1, 2017 - argenx (Euronext Bru...Read more
argenx announces extension of therapeutic antibody alliance with Shire -
Breda, the Netherlands / Ghent, Belgium, February 27, 2017 - argenx (Euronext...Read more
Kuros receives clearance from the US FDA for MagnetOs allowing marketing in the United States -
Schlieren (Zurich), Switzerland, February 27, 2017 - Kuros Biosciences (SIX:...Read more
Neuravi Announces Completion of Patient Enrollment in Clinical Trial of a Novel Stent Retriever for Acute Ischemic Stroke -
ARISE II Data Will Be Submitted to the FDA in Support of Market Clearance for...Read more
Kuros closes acquisition of Xpand creating a leading commercial-stage orthobiologics company -
Schlieren (Zurich), Switzerland, January 25, 2017 - Kuros closes acquisition ...Read more
Curetis’ Global Installed Base Expanding to Over 150 Unyvero Analyzers -
Completion of EMEA Direct Sales team build-out drives 46% growth in syste...Read more
BioCapital Europe 2017, organised by LSP -
BioCapital Europe 2017, organised by LSP, is pleased to announce the keynote ...Read more
LSP’s portfolio company G-Therapeutics named FierceMedicalDevices' 2016 Fierce 15 company -
Amsterdam, The Netherlands, January 23, 2017. It is with great pleasure that ...Read more
Merus Announces Closing of Global Strategic Research Collaboration with Incyte to Discover and Develop Bispecific Antibodies -
UTRECHT, The Netherlands, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDA...Read more
LSP's portfolio company Atlas Genetics raises $35m in Series D fundraising -
Financing global launch and menu development of Atlas Genetics’ io® molecu...Read more
Affimed Announces Pricing of Public Offering of Common Stock -
Heidelberg, Germany January 20, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinica...Read more
LSP's portfolio company Luxendo Announces Series A Extension Bringing Total Capital Raised to €8 Million -
Luxendo intends to use funds to drive the uptake of its Single Plane Illumina...Read more
Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimer's disease patients -
Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study ...Read more
Affimed and MD Anderson Announce Clinical Immuno-Oncology Development Collaboration -
Agreement Brings Together MD Anderson's Natural Killer Cell and Affimed&#...Read more
Curetis Completes Development of Unyvero Cartridge for Intra-Abdominal Infections -
Highly multiplexed panel covers up to 112 diagnostic targets
Third ...Read more
argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravis -
- Topline data from the study expected in second half of 2018 -
Br...Read more
Merus and the Institute for Research in Biomedicine (IRB) Barcelona Form Research Collaboration to Develop Bispecific Antibodies Targeting the Tumor Microenvironment -
UTRECHT, The Netherlands, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDA...Read more
Curetis Files for U.S. FDA Clearance for Unyvero Platform and LRT Application Cartridge -
Final panel demonstrates overall weighted average sensitivity of 91.4% an...Read more
Kuros to acquire Xpand in an all-share strategic transaction to create a leading commercial stage orthobiologics company -
Xpand’s first product MagnetOs, a novel orthobiologic, is approved for ...Read more
LSP’s portfolio company Merus announces global strategic collaboration with Incyte -
LSP’s portfolio company Merus announces global strategic collaboration with...Read more
argenx announces publication of seminal data supporting the therapeutic potential of ARGX-110 for acute myeloid leukemia in the Journal of Experimental Medicine -
Breda, the Netherlands / Ghent, Belgium, December 29, 2016 - argenx (Euronext...Read more
argenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients -
Breda, the Netherlands / Ghent, Belgium, December 15, 2016 - argenx (Euronext...Read more
Kiadis will start trial to treat children with severe blood disorder -
Amsterdam, The Netherlands, December 15, 2016, – Kiadis Pharma N.V. (“Kia...Read more
Curetis Acquires Real-Time qPCR Platform from Carpegen and Systec -
Gyronimo Platform offers rapid, quantitative cartridge-based sample-to-an...Read more
#investEU - Curetis obtains EIB debt financing totaling up to EUR 25 million to further expand its diagnostic platform -
European Investment Bank (EIB) provides EUR 10 million immediately, with ...Read more
LSP led a EURO 32 million investement in OxThera AB -
Amsterdam, the Netherlands, December 9, 2016, OxThera AB, a Stockholm-based p...Read more
Hybrigenics enrolls a first patient in the United States in the clinical study of inecalcitol in acute myeloid leukemia patients unfit for chemotherapy -
Paris, France, 28 November 2016 – Hybrigenics (FR0004153930 - ALHYG), a bio...Read more
Impacting patient lives with new diabetes drug approval -
Amsterdam, Munich, Boston, November 22, 2016 - LSP (Life Sciences Partners), ...Read more
Amyloid-beta (Abeta) aggregate-clearing by the murine anti-pyroglutamate-3 Abeta IgG2a monoclonal antibody PBD-C06 with and without a complement mutation in an Alzheimer's mouse model -
HALLE (SAALE), Germany, 16 November 2016 - Probiodrug AG (Euronext Amsterdam:...Read more
Merus Announces Favorable Decisions in Europe and Japan for Patents Covering Genetically-Modified Mice for Common Light Chain Human Monoclonal Antibodies -
European Patent Office Dismisses Arguments by Regeneron
Favorable Ru...Read more
Wireless brain-spine connection to overcome paralysis -
Prof Grégoire Courtine and Dr. Jocelyne Bloch, both founders of LSP’s port...Read more
Merus strengthens Executive Management Team with the appointment of John Crowley as Chief Financial Officer -
UTRECHT, The Netherlands, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDA...Read more
Merus N.V. Receives €1.5 Million EUREKA Eurostars Grant with Aquila BioMedical Ltd to Jointly Develop Immunological Assays for Identification of Novel Immunomodulatory Bispecific Antibodies -
UTRECHT, The Netherlands and EDINBURGH, UK, Nov. 09, 2016 (GLOBE NEWSWIRE) --...Read more
Merus Expands Executive Management Team with the Appointment of L. Andres Sirulnik, MD, PhD, as Chief Medical Officer -
UTRECHT, The Netherlands, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDA...Read more
Curetis Announces Positive Top Line Data from U.S. FDA Trial -
Primary endpoint for Unyvero LRT product for lower respiratory tract infe...Read more
Merus Receives Milestone Payment from Ono Pharmaceutical for Selection of Bispecific Antibody Candidate for Clinical Development and Extends Partnership with CMC Service Agreement -
UTRECHT, The Netherlands, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDA...Read more
Probiodrug announces pricing of a EUR 14.9 million accelerated bookbuild offering of new shares -
NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, JAP...Read more
Immunic acquires 4SC’s Immunology Portfolio -
Immunic acquires two promising drug development programs with validated targe...Read more
Nouscom Appoints New Chief Operating Officer and Strengthens the Board of Directors -
Basel, Switzerland – 26 September 2016: Nouscom, an oncology company develo...Read more
argenx provides update on lead programs in auto-immune disease and oncology at R&D day in New York -
Myasthenia gravis and immune thrombocytopenia named as initial indication...Read more
LSP Venture Partner Hans Clevers gets prestigious “Körber Award” for his ground breaking research into stem cells and organoids, and appears in German prime time television news -
To see the video click here
...Read more
LSP Leads EUR 16.2M Financing Round in Vivasure Medical to Advance Commercialization of its Closure Device in the European Union and entry into the United States -
Amsterdam, the Netherlands —September 8, 2016 — LSP (Life Sciences Partne...Read more
Neuravi Announces European Launch of EmboTrap II Stent Retriever for the Treatment of Acute Stroke -
Advancements to Stent Retriever Platform Designed to Enhance Procedure
...Read more
Promising new findings for Probiodrug's Glutaminyl Cyclase - inhibitor in an inflammation animal model -
Promising new findings for Probiodrug's Glutaminyl Cyclase - inhibitor in...Read more
ViCentra appoints two new medical and scientific advisors -
6th September 2016
ViCentra, manufacturer of the Kaleido insulin d...Read more
Curetis to Launch Next Generation CE-IVD Unyvero Implant and Tissue Infection Application Cartridge -
Launch follows successful completion of CE Performance Evaluation Study
...Read more
LSP’s Portfolio Company Mint Solutions Raises € 5 Million in Series B Financing Round -
Amsterdam, the Netherlands, August 25, 2016 – LSP’s portfolio company Min...Read more
argenx Reports Second Quarter Business Update and Half Year 2016 Financial Results -
Successful Phase 1 multiple ascending dose (MAD) study of ARGX-113 in hea...Read more
Kiadis featured in German "Aktionärsbrief" -
Click here to see the full article.
...Read more
Curetis Completes Sample Enrollment in Unyvero U.S. FDA Trial in Lower Respiratory Tract Infections -
Last patient enrolled in prospective arm of IVD trial
More than 2...Read more
Curetis Announces Excellent Study Data and Multi-Region Launch of Unyvero BCU Blood Culture Application Cartridge -
- Interim data from prospective multicenter evaluation show 98% concordance w...Read more
argenx announces efficacy and expanded safety data from Phase 1 trial of ARGX-111 -
Additional preclinical data support potential of ARGX-111 in targeting tumor ...Read more
Merus Signs Commercial Multi-Product License for ProBioGen’s GlymaxX® ADCC Enhancement Technology -
Bispecific Cancer Antibody Pipeline Optimized by GlymaxX® Manufacturing Tech...Read more
argenx announces private placement of 2,703,000 new shares for an aggregate amount of €30 million with institutional investors -
Breda, the Netherlands / Ghent, Belgium - June 01, 2016 – argenx (Euronext...Read more
LSP’s portfolio company Merus listed on NASDAQ -
Our portfolio company Merus, based in Utrecht, the Netherlands, got liste...Read more
Nouscom concludes successful series A financing of EUR 12 million -
Basel, Switzerland – May, 17 2016 -- Nouscom announced today that it has cl...Read more
eTheRNA strengthens management team with appointment of Dr. Karl-Josef Kallen as Chief Medical Officer -
eTheRNA immunotherapies, the VUB spin-off that recently secured a EUR 24 mi...Read more
Merus Announces First Patient Dosed in Phase 1/2 Trial Evaluating Bispecific Antibody Candidate MCLA-117 in Patients with AML -
UTRECHT, The Netherlands, May 04, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clin...Read more
LSP’s portfolio company argenx and AbbVie to collaborate on ARGX-115 against novel immuno-oncology target -
Amsterdam, the Netherlands – 21 April 2016 – AbbVie (NYSE: ABBV), a globa...Read more
LSP co-leads Series A financing of G-Therapeutics that raises EUR 36 mln to develop its neuro-stimulation therapy for spinal cord injury -
Amsterdam, the Netherlands – 19 April 2016 – G-Therapeutics announces tod...Read more
Merus to Present Interim Clinical Data from Ongoing Phase 1/2 Clinical Trial of its Lead Bispecific Antibody Candidate, MCLA-128, at the American Association for Cancer Research 2016 Annual Meeting -
MCLA-128 Shows Favorable Safety Profile and Early Signs of Anti-Tumor Activit...Read more
New topinstitute for cancer launched in The Netherlands -
The Netherlands has a very strong science base in for example oncology, but t...Read more
Kiadis Pharma proposes Robert Soiffer and Berndt Modig as its new Supervisory Board members -
Amsterdam, The Netherlands, April 7, 2016 – Kiadis Pharma N.V. (“Kiadis P...Read more
Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101™ -
Significant increase in Overall Survival and reduction in Transplant Rela...Read more
Curetis to Launch CE-IVD Unyvero Blood Culture Application Cartridge at ECCMID 2016 -
- Successful completion of CE Performance Evaluation Study
- Covers 103 d...Read more
Probiodrug Appoints Mark Booth as Chief Business Officer -
Expands Management Board with Senior Hire
HALLE/SAALE, Germany, 23...Read more
ETheRNA, een spin-off van de VUB, werkt aan een immuuntherapie met een 'drievoudige boost' -
ETheRNA, een spin-off van de VUB, werkt aan een immuuntherapie met een 'd...Read more
Bio€quity 2016 -
LSP is a sponsor of the Bio€quity Europe 2016 in Copenhagen, Denmark.
T...Read more
LSP leads EUR 24 mln Series A financing of eTheRNA to develop its TriMix mRNA-based immunotherapy -
Amsterdam, the Netherlands – 14 March 2016 – eTheRNA immunotherapies, a s...Read more
TiGenix announces positive 52-week Phase III results of Cx601 in complex perianal fistulas in Crohn's disease patients -
A single injection of Cx601 was statistically superior to placebo in achi...Read more
Curetis Starts Final Validation Study for New Unyvero Blood Culture Application Cartridge -
- Data and CE-IVD launch expected in Q2, 2016
- Company also prepar...Read more
First full hospital roll-out of MedEye in the Netherlands -
LSP’s portfolio company Mint Solutions provides for the first time an entir...Read more
Digital health and medtech come alive -
Healthcare investing comes of age
The stage is all set for another good ...Read more
Atlas Genetics Gains CE Approval for First Product -
Approval of Chlamydia test for marketing and sale in Europe
Bath, ...Read more
LSP’s Nexstim and its impact in brain surgery -
For more info click here
...Read more
Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes -
The Phase 2 trial is an important step in the dual product development of...Read more
Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Hodgkin Lymphoma -
Heidelberg, Germany, January 25, 2016 - Affimed N.V. (Nasdaq: AFMD), a clin...Read more
Curetis Expands Commercial Team -
- Company hires Willem Haagmans as Head of Sales EMEA -
Amsterdam,...Read more
Agenus Announces Clearance of Investigational New Drug Applications by the FDA for anti-CTLA-4 and antiGITR Antibodies -
Clinical studies for both checkpoint modulator antibodies allowed to commence...Read more
LSP’s portfolio company Kuros closes merger with Cytos and is now listed as Kuros Biosciences Ltd on Swiss stock exchange -
Amsterdam, the Netherlands – 20 January 2016 – Our portfolio company Kuro...Read more
argenx announces € 16 M investment by US funds advised by subsidiaries of Federated Investors -
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOL...Read more
LSP Leads Financing Round in Insulin Pump Company ViCentra -
Amsterdam, the Netherlands, 20 January 2016. LSP (Life Sciences Partners), a ...Read more
Merus and Gustave Roussy Form Strategic Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Immuno-Oncology Applications -
UTRECHT, The Netherlands and VILLEJUIF, France, Jan. 04, 2016 (GLOBE NEWSWIRE...Read more
Sanofi Submits New Drug Application for the Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide -
Paris, France - December 23, 2015 - Sanofi announced today that it has submit...Read more
Nexstim announces the result of its private placement -
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR...Read more
Xeltis extends series B financing to €30M, signing off transformational year -
In 2015: positive results from first two clinical trials, stronger leadership...Read more
Merus Appoints Hui Liu as Chief Business Officer -
Novartis Oncology’s Former Global Head of Business Development and Licensin...Read more
Affimed Added to NASDAQ Biotech Index® -
Heidelberg, Germany, December 14, 2015 - Affimed N.V. (Nasdaq: AFMD), a clini...Read more
Probiodrug announces publication of initial PQ912 clinical data demonstrating inhibition of glutaminyl cyclase -
PQ912 is currently in Phase 2a studies in Alzheimer’s disease patients
...Read more
Hybrigenics receives green light for a double-blind placebo-controlled Phase II clinical study of inecalcitol in Acute Myeloid Leukemia (AML) -
Hybrigenics has received the authorization by the French Drug Agency to p...Read more
Nexstim Plc Announces Completion of Enrolment of Phase III Clinical Trial in Stroke Therapy -
- Recruitment completed ahead of schedule
Helsinki, 3 December 201...Read more
LSP V company Kuros to combine with Cytos -
Cytos Biotechnology and Kuros Biosurgery to combine to create Kuros Bioscienc...Read more
LSP and Bristol-Myers Squibb enter into strategic collaboration for life sciences innovation in Europe -
First investment by Bristol-Myers Squibb in a European healthcare fund
...Read more
LSP: A European Venture Fund Invests in the Economics of Medtech -
Amsterdam, 17 November 2015 – For a recent in-depth article on the LSP Heal...Read more
Xeltis completed second feasibility clinical trial on bioabsorbable cardiovascular device technology -
Xeltis developing first cardiac valves and vessels designed to allow endogeno...Read more
LSP’s portfolio company Curetis raises EUR 40 million in successful Euronext IPO -
Amsterdam, the Netherlands - 12 November 2015 - Our portfolio compan...Read more
Probiodrug announces pricing of a EUR 13.5 million private placement of new shares -
NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, JAP...Read more
Kiadis Pharma announces maiden Financial Results for the six months ended 30 June 2015 -
Amsterdam, The Netherlands, August 25, 2015 – Kiadis Pharma N.V. (“Ki...Read more
LSP invests in Kuros, a late-stage sealant and orthobiologics company -
Amsterdam, The Netherlands, 18 August 2015. LSP (Life Sciences Partners), a l...Read more
Merus enters into 72.8 million euro series C financing led by Sofinnova Ventures and Novo A/S -
UTRECHT, Netherlands, Aug. 26, 2015 /PRNewswire/ -- Merus B.V., a clinical-st...Read more
LSP raises EUR 80 mln to invest in medical innovations -
Not for distribution or release directly or indirectly, in or into the Un...Read more
Can we train our bodies to fight cancer? -
While tremendous strides have been made in the fight against cancer – the b...Read more
Kiadis Pharma Announces Full Enrolment of its Phase II Clinical Study with Lead Product, ATIR101™ -
~ The target 23 patients have now been enrolled ~
Amsterdam, the N...Read more
Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH) - - MYDICAR When Inhaled May Restore Function of SERCA2a Enzyme in the Lungs to Re...Read more
Celladon's gene therapy for heart failure takes spotlight in the U.K. - By John Carroll, FierceBiotech
San Diego-based Celladon has made a big splash...Read more
Prosensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer -
Leiden, The Netherlands, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Prosensa Holding N...Read more
Hybrigenics revenues grew 45% to EUR 6.6 million in 2011 - Hybrigenics Services contributed for EUR 4.1 million, a 17% growth
In 2011, H...Read more
Former LSP company Okairos working on Ebola -
A link to the press release can be found here
...Read more
Celladon Corporation Announces First Patient Dosed in CUPID Phase 2b Trial of MYDICAR® for Advanced Heart Failure - San Diego, California, August 29, 2012/PRNewswire/ -- Celladon Corporation, a bi...Read more
Zealand and Boehringer Ingelheim sign second collaboration agreement to advance novel peptide medicines -
─ Zealand eligible to receive up to EUR 295 million in potential milestone ...Read more
arGEN-X presents preliminary efficacy and expanded safety data from Phase I trial of ARGX-111 at ASCO -
Safe dose established for next stage studies
Biological activity ...Read more
GSK strengthens vaccines business with acquisition of Okairos - Issued: Wednesday 29 May 2013, London UK
GSK strengthens vaccines business wi...Read more
Celladon Corporation Selected as Winner of Red Herring's "Top 100 North America Tech Startup" - SAN DIEGO, May 29, 2013 /PRNewswire/ -- Celladon Corporation, a biopharmaceutica...Read more
LSP leads a CHF 23 million Series C investment in Sequana Medical -
Amsterdam, The Netherlands, 28 April 2014. LSP (Life Sciences Partners), a le...Read more
AGENUS ANNOUNCES COLLABORATION AND LICENSE AGREEMENT WITH MERCK FOR NOVEL CHECKPOINT ANTIBODY-BASED CANCER IMMUNOTHERAPIES -
• Agenus is eligible to receive ~$100 million in milestone payments as well...Read more
Bryan, Garnier & Co initiates coverage of Hybrigenics with a target price of €2.6 - Paris, March 29, 2012 – Hybrigenics SA (ALHYG), a bio-pharmaceutical company l...Read more
arGEN-X enters into a therapeutic antibody alliance with Shire - HUMAN ANTIBODY PRODUCT COLLABORATION IN RARE DISEASES
Rotterdam, the Netherla...Read more
Prosensa Achieves Orphan Drug Status on its Entire Duchenne Muscular Dystrophy Portfolio - Leiden, The Netherlands – 29 January 2013 – Prosensa, the Dutch biopharmaceu...Read more
4-Antibody AG and the Ludwig Institute Expand Oncology Antibody R&D Program with Three New Targets - Basel, Switzerland and New York, NY, 29 Jan, 2013: 4-Antibody AG and the Ludwig ...Read more
Okairos named as one of Windhover’s Top Projects to Watch in infectious diseases - Basel, Switzerland – 28 November 2012 – Windhover Information has named Okai...Read more
LSP Health Economics Fund co-leads $28 Million Series C Financing round of IlluminOss - Amsterdam - Boston – September 28, 2012 – LSP Health Economics Fund is pleas...Read more
Nexstim Progresses its Navigated Brain Stimulation Technology in Stroke and Demonstrates Improved Outcomes in Brain Tumor Surgery -
• Study on track and sites selected and initiated in multicenter clinical t...Read more
Prosensa Announces Second Quarter 2013 Financial Results and Recent Corporate Developments - Raised $89.7M with successful IPO, providing substantial base to support develop...Read more
LSP company Prosensa successfully listed on NASDAQ -
It is with great pleasure that today, LSP – the specialist European healthc...Read more
Lyxumia® is first diabetes therapy of its class approved in Japan for use in combination with basal insulin - - First once-daily prandial GLP-1 receptor agonist offering a new treatment opti...Read more
arGEN-X announces collaboration with Bayer to discover and develop therapeutic antibody candidates -
Breda, the Netherlands, 28 May 2014 – arGEN-X, a clinical-stage biopharmace...Read more
LSP portfolio company Agenus in the press -
Please find two links to press releases issued this week by Agenus www.agenus...Read more
Hybrigenics full year 2014 results -
Strong cash position further recently increased by EUR 9 million
Par...Read more
BioCapital Europe - Presenting companies announced -
BioCapital Europe, Europe's premier life sciences investment conference ...Read more
Leve de wetenschap -
De Nederlandse wetenschap is top. Durfinvesteerder LSP schrijft het nog eens ...Read more
LSP's portfolio company EyeSense enters strategic partnership with Lee’s Pharmaceutical Holdings -
Through the attached press release we are happy to announce the strategic par...Read more
Curetis AG Signs Up BioLine LLC as Exclusive Distribution Partner for Russia - Partners to start registration process and market launch in Russia
Holzgerlin...Read more
Biotech Update 2013 - Biotech Update 2013
Friday 28th June 2013
Kasteel De Wittenburg in Wassenaar, ...Read more
SUPPRESTEM Consortium Led by Merus Receives €6 Million FP7 Grant from the European Union - - Development of Therapeutic Bispecific Antibodies (Biclonics™) Targeting Trea...Read more
BioCapital Europe takes place today in Amsterdam -
John P. de Koning, Partner at LSP and conference host, sounded the bell yeste...Read more
Hybrigenics completed its private placement to institutional investors up to EUR 3.3 million - Paris, March 27, 2012 - Hybrigenics SA (ALHYG), a bio-pharmaceutical company lis...Read more
Prosensa Receives Rare Disease Company Award from EURORDIS - Leiden, The Netherlands – 27 February 2013 – Prosensa, the Dutch biopharmace...Read more
Hybrigenics extends its partnership with Servier in the field of Ubiquitin-Specific Proteases inhibitors -
Paris, 26 January 2015 – Hybrigenics (ALHYG), a bio-pharmaceutical company ...Read more
Curetis AG Chooses Mediphos as Exclusive Distribution Partner for the Netherlands - Partners prepare market launch and clinical evaluation project
Holzgerlingen,...Read more
LSP’s portfolio company Sapiens Steering Brain Stimulation acquired by Medtronic for EUR 150 million -
Amsterdam, the Netherlands, 26 August 2014. LSP (Life Sciences Partners), a l...Read more
arGEN-X to Present at Upcoming Ninth Annual PEGS 2013 - Presentations will highlight significant progress made towards development of no...Read more
BioCapital Europe Company of the Year award goes to Prosensa -
Amsterdam, March 26, 2015. At the BioCapital Europe conference being held tod...Read more
--- BIOCAPITAL EUROPE INVESTOR CONFERENCE TO TAKE PLACE ON 27TH MARCH 2014 -
BioCapital Europe 2014, organised by LSP (Life Sciences Partners) is delighte...Read more
Een druppel op de hete financiële gezondheidsplaat -
Het jonge Nederlandse fonds LSP Health Economics Fund heeft 113 miljoen euro ...Read more
Kiadis Pharma Receives Regulatory Approval from Health Canada for a Phase II Clinical Study with its Blood Cancer Treatment ATIR™ - Amsterdam, The Netherlands, February 26, 2013 – Kiadis Pharma B.V., a clinical...Read more
arGEN-X appoints Dr. David L. Lacey to its Supervisory Board - Breda, the Netherlands and Ghent, Belgium October; 25 October 2012 – arGEN-X, ...Read more
OctoPlus announces equity raising with net proceeds of € 3 million -
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CA...Read more
Affimed Announces Financial Results for Fourth Quarter and Year End 2014 -
--Transformative Year for the Company and its Bi- and Trispecific Cancer Immu...Read more
arGEN-X announces preclinical development of ARGX-112 for dermatology - ARGX-112 targets IL22R1, a novel target involved in chronic skin inflammation
...Read more
Okairos initiates Phase I clinical trial evaluating vaccine against RSV infections - Basel, Switzerland – 25 February 2013 – Okairos today announced the initiati...Read more
Prosensa Raises €23 Million in New Equity Financing Led by New Enterprise Associates - Leiden, The Netherlands, 25 January 2012 – Prosensa, the Dutch biopharmaceutic...Read more
LSP's portfolio company Prosensa receives tender offer from BioMarin -
Through the attached press release we are very happy to announce the agreemen...Read more
LSP invests in Curetis, a leading molecular diagnostics company -
Amsterdam, the Netherlands, 24 November 2014. LSP (Life Sciences Partners), a...Read more
LSP’s Portfolio Company Probiodrug listed on Euronext Amsterdam -
Our portfolio company Probiodrug AG, based in Halle/Saale, Germany, ...Read more
Curetis’ Unyvero System Selected for Global Phase III Antibiotics Trial -
• Unyvero to be used for pathogen identification and patient inclusion at s...Read more
New Favorable Clinical Evaluation Data for Unyvero™ P50 Pneumonia Application -
Dutch study demonstrates excellent sensitivity of Unyvero™ cartridges ...Read more
arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders - First program based on proprietary ABDEG™ technology to promote degradation an...Read more
Hybrigenics’ specific inhibitors of Ubiquitin-Specific Protease 7 (USP7) are cytotoxic for human cancer cell lines in vitro - The mechanism of USP7 inhibition and the resulting decrease in viability of huma...Read more
arGEN-X granted first US patent covering its unique NHance™ technology - Rotterdam, the Netherlands and Ghent, Belgium April 24, 2012 – arGEN-X, a biop...Read more
Affimed Completes TandAb Development Candidate Activities Meeting Amphivena's and Janssen's Criteria and Achieves Milestone Ahead of Schedule -
-- Cancer Immunotherapy Development Candidate Selection Triggers Milestone Pa...Read more
Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR™ - Amsterdam, The Netherlands, January 21, 2013 – Kiadis Pharma B.V., a clinical ...Read more
TiGenix secures EUR 10 million in financing from Kreos Capital Company ends year in strong position to fully leverage leading cell therapy platform - Leuven (BELGIUM) – December 23, 2013 – TiGenix (Euronext Brussels: TIG) anno...Read more
Merus Granted European Patent on MeMo®, a Transgenic Mouse for Generating the Building Blocks of Therapeutic Human Bispecific Antibodies - - Invention provides unique technology base for therapeutic human bispecific ant...Read more
Prosensa Announces Progress on Exon Skipping Compounds for the Treatment of Duchenne Muscular Dystrophy - £10m in milestone payments received from GlaxoSmithKline
Leiden, The Netherl...Read more
Kiadis Pharma to receive GMP manufacturing license and GMP certificate - Amsterdam, The Netherlands, July 23, 2013 – Kiadis Pharma B.V., a clinical sta...Read more
arGEN-X Announces Publication on Therapeutic Potential of Antibody ARGX-115 in Cancer Immunotherapy -
Results on ARGX-115 published in Science Translational Medicine indicating in...Read more
Save the Date: BioEquity Europe 2012 - May 15-16 - BioEquity Europe 2012
May 15-16, 2012
Frankfurt (Main), Germany...Read more
Save the Date: BioTech Update 2012 - June 12 - BioTech Update 2012
June 12th
Wassenaar, The Netherlands...Read more
Probiodrug AG Strengthens Management Team and Expands Global Reach with Appointments of Ronald Black and Inge Lues - HALLE/SAALE, Germany, January 23, 2013 – Probiodrug AG (Probiodrug) today anno...Read more
Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office - -Patent will provide IP protection relative to Celladon's small molecule program...Read more
Hybrigenics 2013 first-half results Update on the development of inecalcitol -
+9% growth of Hybrigenics’ operating revenues
60% biological respo...Read more
Curetis Presents First Data on Novel Unyvero™ i60 ITI Application for Implant and Tissue Infections - New cartridge detects 114 targets
Roll-out in collaboration with Heraeus Medi...Read more
Hybrigenics’ inecalcitol receives positive opinion from EMA for orphan drug designation in acute myeloid leukemia -
Paris, 22 June 2015 – Hybrigenics (ALHYG), a bio-pharmaceutical company lis...Read more
Prosensa wins “Emerging Star Award” at the European Mediscience Awards - Leiden, The Netherlands, 22 June 2012 - Prosensa, the Dutch biopharmaceutical co...Read more
STALLERGENES AND ACTOGENIX TO DEVELOP AN INNOVATIVE NEW CLASS OF ORAL ALLERGY TREATMENTS -
STALLERGENES exercised option to pursue the exclusive development of applicat...Read more
arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions -
Breda, the Netherlands/Ghent, Belgium and Ballerup, Denmark, May 21, 2015 –...Read more
Hybrigenics launches Phase II clinical study of inecalcitol in chronic myeloid leukemia -
Paris, 19 January 2015 – Hybrigenics (ALHYG), a bio-pharmaceutical company ...Read more
Zorgverzekeraars stappen massaal in nieuw fonds -
Door Hans Maarsen
Life Sciences Partners in Amsterdam, behorend tot de gr...Read more
Should I have my DNA analyzed? -
By Geraldine O'Keeffe
According to the advertisement, for as little ...Read more
Prosensa listed on NASDAQ raising $ 100 million -
It is with great pleasure that today, LSP – the specialist European healthc...Read more
Kiadis Pharma Raises EUR 10 Million in Financing Round - Amsterdam, The Netherlands, November 20, 2012 – Kiadis Pharma B.V., a clinical...Read more
SAVE THE DATE: Biotech Update 2013 - Biotech Update 2013
Friday 28th June 2013
Kasteel De Wittenburg in Wassenaar, ...Read more
BioCapitalEurope 2013 - BioCapitalEurope
Wednesday 17th April 2013
BioCapital Europe 2013, organis...Read more
Pasteuria Bioscience to be Acquired by Syngenta - Amsterdam and Boston, September 20, 2012 - LSP is pleased to announce that Synge...Read more
Curetis and Heraeus Medical Collaborate on the Development of New Unyvero™ Diagnostic Cartridge - Joint development of cartridge for orthopaedics, wound and surgery infections
...Read more
Hybrigenics’ inecalcitol shows synergy with azacytidine in preclinical models of Acute Myeloid Leukemia -
Results are presented today at the 17th Vitamin D Workshop in Chicago, USA
...Read more
Merus receives EP patent covering the expression of defined antibody combinations - Utrecht, The Netherlands, June 20, 2012 – Merus B.V., a biopharmaceutical comp...Read more
Merus and Selexis receive a € 2.1 million grant for single cell line manufacturing of a bispecific antibody combination to treat colorectal cancer -
Utrecht, The Netherlands, May 20, 2015 -- Merus B.V., a leader in developing ...Read more
Hybrigenics’ inecalcitol gets Orphan Drug designation for the treatment of Chronic Lymphocytic Leukemia in the United States -
Paris, 20 May 2014 : Hybrigenics (ALHYG), a bio-pharmaceutical group list...Read more
Hybrigenics Services wins the Life Science Award of the “Most Innovative New Service” of the yearat the 4th annual European Lab Automation Exhibition -
Paris, 19 May 2014 – Hybrigenics (ALHYG), a bio-pharmaceutical group listed...Read more
Exciting stuff at the BioCapital Europe 2015 Conference -
March 26, LSP organized the BioCapital Europe Conference for the 13th consecu...Read more
arGEN-X launches NHance™ technology to generate better human antibody therapies - adds a second proprietary technology to leverage the power of the SIMPLE Antibod...Read more
Pronota announces EUR 3.7 million Series C financing; management and board changes - Ghent, Belgium; Pronota NV today announced the close of a Series C financing, ra...Read more
Menzis investeert met LSP Health Economics Fund in zorginnovaties - Amsterdam, 19 oktober 2012 – Dit voorjaar werd het LSP Health Economics Fund (...Read more
arGEN-X completes recruitment of first cohort of 15 patients with CD70-positive solid tumors into its Phase 1b expansion trial with ARGX-110 -
18 September 2014
Breda, the Netherlands / Ghent, Belgium - arGEN-...Read more
Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech - San Diego, California, September 19, 2012/PRNewswire/ -- Celladon Corporation, a...Read more
Three LSP portfolio companies nominated to the 2012 Fierce 15 list - Amsterdam, September 19, 2012 – Life Sciences Partners (LSP), the European hea...Read more
Celladon Corporation Receives Patent from United States Patent and Trademark Office - -Patent will further expand intellectual property protection for MYDICAR® – a...Read more
Biotech Update Wassenaar -
We have seen a very successful year for the life science industry with an...Read more
Probiodrug receives 2015 European Mediscience Award for Best Technology -
HALLE/SAALE, Germany, 12 June 2015 – Probiodrug AG (Euronext Amsterdam: PBD...Read more
LSP’s Clemens van Blitterswijk welcomes the King at MERLN -
LSP’s Clemens van Blitterswijk welcomes the King at MERLN
http://www.m...Read more
Hybrigenics targets chronic lymphocytic leukemia (CLL) as the third therapeutic indication for its oral inecalcitol - Hybrigenics filed a clinical trial application to test inecalcitol, a vitamin D ...Read more
LSP raises € 112 mln for its Health Economics Fund, exceeding target -
Amsterdam, The Netherlands, 7 March 2014. LSP (Life Sciences Partners), a lea...Read more
Nexstim Launches Next Generation NBS 5 System -
Helsinki, 18 September 2014
Nexstim (the “Company”), a medical...Read more
Activaero’s partner ablynx initiated phase I studies in Respiratory Syncytial Virus (RSV) using favorite technology -
Gemuenden/Wohra, Germany, July 18, 2013 - Activaero GmbH, the therapeutic are...Read more
Curetis AG Signs Distribution Deal in Middle East with ATC - Holzgerlingen, Germany, July 18, 2012 -- Curetis AG, an innovative molecular dia...Read more
arGEN-X presents preliminary Phase I results of ARGX-110 in patients with T-cell lymphomas at ICML -
Breda, The Netherlands / Ghent, Belgium, June 17, 2015 - arGEN-X N.V. (Eu...Read more
Celladon Corporation Receives Notice of Allowance from European Patent Office - -Patent will expand intellectual property protection for MYDICAR – a first in ...Read more
Merus announces appointment of Jason Avery as Chief Business Officer - Utrecht, The Netherlands, June 15, 2012 – Merus B.V., a biopharmaceutical comp...Read more
MDD Interview: Nexstim targets $1.8B with brain stimulation for stroke therapy -
Europe Editor
On the strength of a 29-patient Phase II clinical study th...Read more
ActoGeniX closes EUR 10.7 million financing round - ActoGeniX, a clinical stage biopharmaceutical company, successfully closed a Ser...Read more
Better diagnosis of acute heart failure using Pronota’s novel biomarker -
Two independent validation studies demonstrate that Pronota’s biomarker CD1...Read more
ARGX-110, a novel anti-CD70 antibody, meets translational development goals in dose escalation part of Phase Ib cancer study - Dose confirmed for Phase Ib safety and efficacy expansion study
17 December 2...Read more
ActoGeniX Announces Positive Results From a Phase 1 Study of AG014; Oral Capsule Administration of an Anti-TNF-Alpha Antibody for the Treatment of Inflammatory Bowel Disease -
AG014 Safe and Well Tolerated, Successful Localized GI Delivery of Drug With
...Read more
ARGEN-X initiates phase Ib study of ARGX-111 in cancer -
SIMPLE Antibody™ with unique mode of action addressing c-Met positive tumor...Read more
LSP leads EUR 19M Financing Round in Endovascular Stroke Company Neuravi -
Amsterdam, the Netherlands, 17 June 2015. LSP (Life Sciences Partners), a lea...Read more
Merus Presents Preclinical Data on its Novel Bispecific Antibody MCLA-117 at EHA 2013 - - Clinical Candidate Designed for the Treatment of Acute Myeloid Leukemia (AML) ...Read more
Save the Date: BioCapital Europe 2012 - April 19 -
BioCapital Europe 2012, organised by LSP (Life Sciences Partners) and ABN AM...Read more
Hybrigenics’ inecalcitol receives positive opinion from EMA for orphan designation in chronic lymphocytic leukemia - Paris, 16 December 2013 – Hybrigenics (ALHYG), a bio-pharmaceutical company li...Read more
Affimed Therapeutics and The Leukemia & Lymphoma Society Partner to Advance AFM13 in a Phase 2 Trial for Refractory and/or Relapsed Hodgkin Lymphoma Patients - Heidelberg, Germany, and White Plains, NY, USA, September 16th, 2013: Affimed Th...Read more
Hybrigenics gives an update on the clinical development of inecalcitol -
· End of Phase II study in chronic lymphocytic leukemia (CLL)
· Authori...Read more
Probiodrug Provides Update on Clinical Development of PQ912, its Most Advanced QC-inhibitor for Alzheimer’s Disease - HALLE/SAALE, Germany, July 16, 2013 – Probiodrug AG (Probiodrug) today provide...Read more
Pronota Strengthens Management Team - Former VP Corporate Development Genzyme joins as CBO
Ghent, Belgium, 16 March...Read more
LSP’s portfolio company ActoGeniX to be acquired by Intrexon -
Amsterdam, the Netherlands, 13 February 2015. LSP (Life Sciences Partners), a...Read more
Curetis AG Initiates Prospective Clinical Trial for Rapid Pneumonia Diagnostics - Expected CE-marking and launch in Europe in 2012
Holzgerlingen, Germany, Febr...Read more
arGEN-X Completes Recruitment of First Cohort of 15 Patients with CD70-Positive Hematological Malignancies into its Phase 1b Expansion Trial with ARGX-110 -
Based on evidence of activity, T-cell lymphomas selected as indication for in...Read more
LSP's portfolio company Seahorse Bioscience to be acquired by Agilent Technologies -
Amsterdam - 14 September 2015 - LSP (Life Sciences Partners), a leading Europ...Read more
LSP’s portfolio company Affimed listed on NASDAQ -
Munich/Amsterdam, 15 September 2014. It is with great pleasure that today, LS...Read more
LSP's portfolio company Syntaxin sold to Ipsen - LSP, the specialist European healthcare investor, is proud to announce today the...Read more
Amphivena, a Subsidiary of Affimed AG, Completes $14 Million Equity Financing and Signs Agreement with Janssen - Heidelberg, Germany, July 15th, 2013: Affimed Therapeutics AG, the therapeutic T...Read more
Affimed to Present Data at ASCO to Highlight Potency of NK-Cell-Engaging Combination Therapy with Checkpoint Modulators -
--Further Posters to be Presented on Translational Data for CD33/CD3-TandAb P...Read more
Mayo Clinic’s Dr. Robin Patel Named Principal Investigator for Curetis’ Unyvero™ LRT Trial -
- Curetis adds six new trial sites, significantly expanding U.S. clinical tri...Read more
arGEN-X - Third Quarter Business Update -
Breda, The Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: AR...Read more
LSP co-leads Luxendo Series A financing round -
Amsterdam, The Netherlands, October 14, 2015 – Luxendo, a start-up company ...Read more
arGEN-x N.V. Announces Changes to the Board of Directors -
Breda, The Netherlands / Ghent, Belgium, April 14, 2015 - arGEN-X N.V. (Euron...Read more
Okairos announces initiation of Phase I/II clinical trial for potential first-in-class hepatitis C vaccine - Basel, Switzerland – 14 March 2012 – Okairos today announced the initiation ...Read more
OcellO and Merus sign agreement for screening bispecific cancer antibodies - Leiden and Utrecht, The Netherlands, January 14, 2013 - OcellO B.V. and Merus B....Read more
Henri Termeer joins Prosensa as Strategic Advisor - Leiden, The Netherlands – 13 December 2012 – Prosensa, the Dutch biopharmace...Read more
Nexstim launches its Initial Public Offering and will apply for dual listing on Nasdaq First North Finland and Nasdaq First North Sweden -
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR...Read more
LSP Portfolio company Harvest Automation featured on Bloomberg TV - Harvest Automation, a portfolio company of the LSP Bioventures fund, is featured...Read more
Skyline Diagnostics BV and LabPMM GmbH are proud to announce a new commercial testing service for Acute Myeloid Leukemia (AML) patients in Europe - As of June 15, 2012, a comprehensive molecular diagnostic testing service is ava...Read more
Affimed N.V. Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares -
Heidelberg, Germany, May 12, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical-s...Read more
Probiodrug reports First Quarter 2015 Business Update -
HALLE/SAALE, Germany, 13 May 2015 – Probiodrug AG (Euronext Amsterdam: PBD)...Read more
Are we becoming allergic to our planet? -
Over the past 50 years rapid technological advances and rising standards of l...Read more
LSP invests in Cardiac Dimensions, a pioneer in heart failure treatment -
Amsterdam, the Netherlands, March 13 2015. LSP (Life Sciences Partners), ...Read more
Hybrigenics gets approval and financing for a Phase II clinical trial of oral inecalcitol in chronic lymphocytic leukemia (CLL) - The French drug agency approves a Phase II study of oral inecalcitol in CLL, an ...Read more
ARGEN-X identifies potent antibody antagonists against complex chronic pain target Nav1.7 -
Breakthrough data to be presented during the ‘Discovery on Target’ confer...Read more
Curetis Strengthens Executive Team; Appoints Dr. Achim Plum as Chief Commercial Officer -
• Former Siemens Healthcare manager adds broad expertise in molecular diagn...Read more
LSP sounds the opening bell of the NYSE Euronext Stock Exchange - https://www.youtube.com/watch?v=0zdV3vCSfXE&feature=player_embedded
See also ...Read more
TiGenix to obtain national reimbursement in Spain for its innovative cartilage therapy ChondroCelect® - Leuven (BELGIUM), Madrid (SPAIN) – March 12, 2013 – TiGenix NV (Euronext Bru...Read more
Activaero initiates proof of concept trial with Lasag in severe influenza -
Gemünden/Wohra, Germany, February 12, 2013: Activaero GmbH, the therapeutic ...Read more
arGEN-X Launches Innovative Access Program -
Program extends reach of proprietary SIMPLE Antibody™ platform and creates ...Read more
arGEN-X Announces Advancement of Therapeutic Antibody Alliance with Shire -
Shire to take one or more collaborative product candidates into preclinical d...Read more
GSK strengthens vaccines business with acquisition Okairos for € 250 million -
GlaxoSmithKline (GSK) today announced that it has acquired Okairos AG (Okairo...Read more
Celladon Corporation Announces First European Patient Dosed in CUPID Phase 2b Trial of MYDICAR® for Advanced Heart Failure - SAN DIEGO, Dec. 11, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutic...Read more
arGEN-X Initiates Clinical Efficacy Evaluation of ARGX-110 in Patients with Relapsed/Refractory CD70-Positive T-Cell Lymphomas -
Breda, The Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: AR...Read more
Hybrigenics acquires the genomic activities of Imaxio Pradeyrol Development invests EUR 1.3 million in Hybrigenics - Paris, 11 October 2013 – Hybrigenics (ALHYG), a bio-pharmaceutical company lis...Read more
LSP exits BMEYE to Edwards Lifesciences - LSP is proud to announce that it has sold its portfolio company BMEYE to Edwards...Read more
Hybrigenics starts Phase II clinical trial of inecalcitol in chronic lymphocytic leukemia - Paris, 11 September 2012 – Hybrigenics (ALHYG), a bio-pharmaceutical company l...Read more
LSP’s portfolio company arGEN-X raises targeted EUR 40 million in successful IPO on Euronext -
Amsterdam, the Netherlands, 10 July 2014. It is with great pleasure that toda...Read more
LSP leads a EUR 4.4 million Series A investment in Mint Solutions -
Amsterdam, the Netherlands, 8 July 2014. LSP (Life Sciences Partners), a lead...Read more
Hybrigenics first half 2013 revenues: robust 12% growth - Paris, 11 July 2013 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed...Read more
Atlas participates in £1.5m Grant Funding Award -
Simultaneous Detection of Infection and Antibiotic Resistance
Bath, ...Read more
PMV and LSP enter into strategic partnership in life sciences -
PMV and LSP enter into strategic partnership in life sciences
Brus...Read more
Hybrigenics’ inecalcitol gets Orphan Drug designation for the treatment of Acute Myeloid Leukemia in the United States -
Hybrigenics’ American clinical expenses eligible to US Orphan Drug tax cred...Read more
LSP leads a USD 27.2 million Series B investment in Rotation Medical -
Amsterdam, the Netherlands, 10 July 2014. LSP (Life Sciences Partners), a lea...Read more
Prosensa Completes Enrollment in Natural History Study of Duchenne Muscular Dystrophy -
Leiden, The Netherlands, June 25, 2014 - Prosensa Holding N.V. (NASDAQ: RNA),...Read more
Celladon Corporation Announces New Clinical Development Initiatives for MYDICAR(R) -
SAN DIEGO, July 7, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN...Read more
Mendor raises € 6,5 Million growth financing -
Espoo, Finland - Mendor, a leading diabetes technology company, is pleased to...Read more
arGEN-X raises €40 million in successful Initial Public Offering on Euronext Brussels -
Breda, the Netherlands / Ghent, Belgium, 8 July 2014 – arGEN-X N.V. (“arG...Read more
arGEN-X and The Leukemia & Lymphoma Society Partner on the Development of ARGX-110 for the Treatment of Waldenström’s Macroglobulinemia -
10 June 2014
Breda, the Netherlands / Ghent, Belgium and White Pla...Read more
Nexstim Selected as a 2014 Red Herring Top 100 Europe -
The Only Medical Device Company Awarded
Helsinki, Finland (April 9...Read more
CUPID 2 Results Expected in April 2015 -
SAN DIEGO, March 4, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLD...Read more
Hybrigenics’ inecalcitol shows promising potential in Acute Myeloid Leukemia -
Preclinical results are presented today at the 12th International Congress on...Read more
Curetis Prepares Launch of Second Unyvero™ Application -
Final clinical performance evaluation study for Unyvero™ i60 ITI applicatio...Read more
Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR(R), Novel, First-in-Class Therapy in Development to Treat Heart Failure -
MYDICAR is First Gene Therapy Reported to Receive Breakthrough Designation Fr...Read more
AbCheck Antibody Discovery Deal with Pierre Fabre -
Plzen, Czech Republic; April 2nd, 2014: AbCheck s.r.o., the multi antibody di...Read more
ARGEN-X USES ITS SIMPLE ANTIBODY™ PLATFORM TO IDENTIFY FOUR ‘HOTSPOTS’ ON MET AS TARGETS FOR ITS THERAPEUTIC ANTIBODY PROGRAM -
New findings to be presented at the American Association for Cancer Research ...Read more
Hybrigenics launches Helixio, its new branch dedicated to genomic services -
Paris, 03 April 2014 – Hybrigenics (ALHYG), a bio-pharmaceutical group list...Read more
LSP proud sponsor of the Mediscience Awards 2014 -
Voting Deadline: May 9th
Shortlist announced: May 22nd
...Read more
Achmea en LSP lanceren het LSP-Health Economics Fund voor innovatie in de zorg - Zeist / Amsterdam, 10 februari 2012 – Verzekeraar Achmea en investeringsmaatsc...Read more
arGEN-X Reports Preclinical Data on ARGX-110 in Chronic Myelogenous Leukemia Model -
Data to be presented at ASH demonstrate potential of ARGX-110 in reversing re...Read more
Kiadis Pharma Presents Positive Data from a Pre-specified Interim Analysis of the Phase II Clinical Program with its Lead Product ATIR™ -
~ Data confirms the potential of ATIR™ in partially matched hematopoietic s...Read more
Curetis Presents New Clinical Validation Data on its Unyvero™ P50 Pneumonia / LRT Application - - Clinical studies from U.S. and Switzerland confirm previous performance data
...Read more
Hybrigenics : green light for two European patents protecting new oral formulations of inecalcitol - Hybrigenics obtains patent protection until 2031 for innovative oral formulation...Read more
Curetis Completes Enrollment for its EU Trial As Planned - Prospective multi-center trial enrolls 800 patient samples in 7 months
Holzge...Read more
Hybrigenics’ patent estate of inhibitors of ubiquitin-specific proteases is expanding -
•Hybrigenics’ patent on its fourth chemical family of inhibitors of ubiqu...Read more
Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy -
Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) -- LEIDEN, The Nether...Read more
Curetis Initiates Prospective Multicenter Unyvero™ Study in Europe - - Study to demonstrate added value of Unyvero™ P50 pneumonia application in cl...Read more
Pronota’s Risk Stratification Test Breaks New Ground in the Early Detection of Pre-term Pre-eclampsia Cases in SCOPE Consortium Study - Ghent, Belgium, July 9, 2012. Pronota NV, a company dedicated to the development...Read more
4-Antibody AG and Evotec AG Form Strategic Collaboration - 4-Antibody and Evotec launch a new high-content screening platform for early ant...Read more
IlluminOss Medical Names Dirk Kuyper as Chief Executive Officer - New CEO Hired to Initiate Commercial Activities in Europe for its Photodynamic B...Read more
Curetis Initiates Clinical CE Performance Evaluation of Unyvero P55 Pneumonia Application -
Clinical study to test more than 400 patient samples
Follows succ...Read more
Probiodrug announces enrolment of first patient in Phase 2 Study of novel Treatment for Alzheimer’s disease -
First patient enrolled at leading Alzheimer Center in Amsterdam
HA...Read more
Major strategic agreement between Incyte and Agenus -
Through the attached link we are happy to inform you about a major strategic ...Read more
LSP’s Clemens Van Blitterswijk receives the prestigious Huibregtsen Prize for 2015 -
Amsterdam, the Netherlands - 7th October 2015 - Clemens van Blitterswijk, par...Read more
Affimed raises EUR 15.5 million in a Series D financing round - Heidelberg, Germany; October 8, 2012: Affimed Therapeutics AG, the therapeutic T...Read more
Biotech Update 2015 – A Sunny Afternoon Discussing Stroke, Sleep and “Immorbidity” -
Amsterdam, July 8, 2015. This year’s Biotech Update seminar, organized by L...Read more
LSP's portfolio company Kreatech sold to Leica - It is with great pleasure that LSP – the specialist European healthcare invest...Read more
TiGenix obtains national reimbursement in the Netherlands for breakthrough cartilage therapy ChondroCelect® - Leuven (BELGIUM) – June 8, 2012 – TiGenix (NYSE Euronext: TIG) announced tod...Read more
Celladon and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference" - -Analysis of Recurrent Heart Failure Hospitalizations in Presence of Informative...Read more
Merus reaches pivotal milestone in bispecific antibody collaboration with ONO PHARMACEUTICAL CO., LTD. -
- Successful product lead identification underscores the strength of Merus’...Read more
LSP’s steady hand -
Published in BioCentury, March 31, 2014
When LSP-Life Sciences Partners ...Read more
Zealand Pharma announces pipeline update - Copenhagen, 2013-03-08 08:28 CET (GLOBE NEWSWIRE) --
─ First European sales...Read more
arGEN-X advances a third therapeutic antibody program into preclinical development -
ARGX-111 IS AN ANTI-C-MET ANTIBODY WITH BROAD APPLICABILITY IN CANCER Rotterd...Read more
Affimed N.V. Announces Pricing of Public Offering of Common Stock -
Heidelberg, Germany, May 6, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical-st...Read more
Curetis Launches Unyvero™ i60 Implant and Tissue Infection Cartridge in Europe -
• Successful completion of CE performance evaluation study covering more th...Read more
TB, HIV and Malaria Vaccine Research Gets Major Boost $2.9 million Grant to Advance Chimpanzee Adenovirus Platform - Rockville, MD, US, Oxford, UK and Basel, Switzerland – 7 May 2013 – Aeras, a...Read more
Celladon Corporation is a Finalist for the 2013 Red Herring Top 100 North America Award - San Diego, California, May 7, 2013/PRNewswire/ -- Celladon Corporation, a biopha...Read more
Celladon Corporation Completes Second Close of Recent Venture Financing - -MPM Capital and LSP Life Sciences Partners join existing Celladon investment sy...Read more
LSP haalt Eur 112 mln op voor Health Economics Fund, ver boven target -
Amsterdam 7 Maart 2014. LSP haalt 112 mln euro op voor zijn Health Economics ...Read more
Kreatech signs supply agreement with lung cancer mutation consortium -
Kreatech to supply REPEAT-FREE™ DNA FISH probes for U.S. National Lung Stud...Read more
Merus Further Expands R&D Capacity - Company Contracts R&D Service Provider FairJourney Biologics
Utrecht, The Net...Read more
Merus Achieves Milestone with Novartis Option Fund - Company Reaches Milestone in Biclonics™ Program Partnered with Novartis
Utr...Read more
Larry Bell, MD Joins Prosensa as Head of Global Regulatory Affairs - Leiden, The Netherlands – 7 February 2013 – Prosensa Therapeutics, the Dutch...Read more
Celladon Corporation Conducts Initial Scale Up of Manufacturing Process for MYDICAR to Commercial Scale -
2,000L Demonstration Batch Completed at Lonza, Houston Facility
SAN ...Read more
Merus Selects Clinical Candidate for the Treatment of Acute Myeloid Leukemia (AML) - Utrecht, The Netherlands, January 7, 2013 – Merus B.V., a biopharmaceutical co...Read more
arGEN-X initiates Phase Ib study of ARGX-110 in cancer - Breda, the Netherlands, and Ghent, Belgium, January 7 2013 – arGEN-X, a biopha...Read more
arGEN-X expands its therapeutic antibody alliance with Shire - New discovery program initiated within 12 months of collaboration start
Breda...Read more
arGEN-X announces grant of broad US patent covering its SIMPLE Antibody™ platform - Breda, the Netherlands, and Ghent, Belgium, December 6, 2012 – arGEN-X, a biop...Read more
Curetis AG Initiates Clinical Trial in the U.S. Towards FDA Clearance - Prospective Multi-Center Trial to Enroll Over 2,000 Clinical Samples
Holzgerl...Read more
ARGEN-X ENTERS LONG-TERM STRATEGIC ALLIANCE WITH SHIRE PHARMACEUTICALS IN THERAPEUTIC ANTIBODIES -
SIGNIFICANTLY EXPANDED RELATIONSHIP CREATED ON BACK OF COLLABORATION SUCCESS
...Read more
Pronota is to receive patent on biomarker for diagnosing renal failure in the US despite Prometheus -
GHENT, BELGIUM, June 6, 2013 – The United States Patent and Trade Office (U...Read more
World first, as patient receives an implanted pump system to manage pleural effusions -
Swiss company’s innovative technology enables the automated management of e...Read more
International Consortium Awarded €6M to Validate Pre-Eclampsia Early Detection Tests - Cork, Ireland and Ghent, Belgium – 5 November 2012 – The European Union has ...Read more
Prosensa Wins Scrip 'Biotech Company of the Year' 2014 Award -
Leiden, The Netherlands, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Prosensa Holdin...Read more
LSP’s portfolio company Nexstim Plc successfully completes its IPO raising EUR 15.3 mln -
Amsterdam, the Netherlands, 4 November 2014. LSP (Life Sciences Partners), a ...Read more
arGEN-X and de Duve Institute/UCL to collaborate on novel immunomodulation therapy in cancer - 4 November 2013
Breda, The Netherlands / Ghent, Belgium – arGEN-X today ann...Read more
arGEN-X raises EUR 5 million from PMV in extension of EUR 32.5 million series B - Funds to advance ARGX-113, a novel antibody fragment approach to promote degrada...Read more
RuiYi (formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a Novel anti-IL-6 Antibody - Initial Development Strategy for Highly Potent Antibody Will be Focused on China...Read more
Setting the new standard in decentralised molecular diagnostics -
Bath, UK, 1 May 2015. Atlas Genetics Ltd (“Atlas” or the “Company”), ...Read more
Merus starts Phase I/II clinical trial for MCLA-128, an ADCC-enhanced bispecific antibody for solid tumors -
- First patient dosed in trial with potent bispecific antibody overcoming res...Read more
Probiodrug AG Raises Additional EUR15 Million to Advance Its Clinical Program - HALLE/SAALE, Germany, Jan. 4 2012 - Probiodrug AG today announced it has secured...Read more
LSP invests in Xeltis, a leading regenerative medicine company -
Amsterdam, the Netherlands, December 2, 2014. LSP (Life Sciences Partners), a...Read more
Probiodrug Publishes Further Evidence Correlating Glutaminyl Cyclase (QC) with Alzheimer’s Disease Pathogenesis and Cognitive Decline - HALLE/SAALE, Germany--(BUSINESS WIRE)-- Probiodrug AG (Probiodrug) and researche...Read more
LSP’s portfolio company Celladon listed on NASDAQ -
“It is with great pleasure that today; LSP – the specialist European heal...Read more
Lonza and Celladon Corporation Establish a Strategic Commercial Manufacturing Collaboration for MYDICAR(R) -
Agreement enhances existing relationship between Celladon and Lonza ...Read more
arGEN-X Submits Investigational New Drug Application to Evaluate ARGX-110 in Waldenström’s Macroglobulinemia -
Breda, The Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: AR...Read more
LSP's portfolio company Activaero sold to Vectura -
Amsterdam/Munich, March 13, 2014
We are happy to inform you that V...Read more
Merus Secures €31 Million in Series B Round Extension - - Investment brings Series B to a total of €47.6 million
- Johnson & Johnson ...Read more
Kiadis Pharma announces it raised an additional € 2.0 million via exercise of the Over-Allotment Option and the end of the stabilisation period in relation to its initial public offering -
Amsterdam, the Netherlands, July 31, 2015 – Kiadis Pharma N.V. (“Kiadis ...Read more
LSP company Kiadis Pharma listed on euronext through IPO -
A PDF version of Kiadis Pharmas' press release can be found here.
...Read more
LSP’s portfolio company Prosensa successfully listed on the Nasdaq - It is with great pleasure that today, LSP – the specialist European healthcare...Read more
Prosensa Announces Regulatory Path Forward for Drisapersen as a Potential Treatment for DMD -
Plans to Submit a New Drug Application to the FDA this Year; Dialogue with EM...Read more
arGEN-X to present results of Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced cancer at ASCO -
Breda, The Netherlands / Ghent, Belgium, 29 May 2014 – arGEN-X will present...Read more
Lonza and Celladon Announce Manufacturing Agreement for MYDICAR® - Agreement will support future clinical trials of Celladon's product candidate MY...Read more
Prosensa Provides Update on Drisapersen -
Re-dosing plans are underway and 96-week data from an open-label extension st...Read more
Hybrigenics successfully raised €6.1 million -
These funds will finance two new clinical Phase II studies of inecalcitol in ...Read more
Inspiring BioCapital Conference -
On March 27th, the prestigious hotel The Grand in Amsterdam set the stage for...Read more
Hybrigenics 2014 revenues and cash -
Scientific services turnover up 3%
Total operating revenues down 3%...Read more
Atlas Genetics completes $20m Series C fundraising -
Funds to accelerate global launch of Atlas io® molecular testing system
...Read more
Affimed Added to Russell 2000® Index -
Heidelberg, Germany, June 30, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical ...Read more
Prosensa holding B.V. prices initial public offering -
Leiden, the Netherlands—June 27, 2013—Prosensa Holding B.V. (“Prosensa...Read more
Hybrigenics acquires Dualsystems Biotech’s yeast two-hybrid (Y2H) activities - Hybrigenics Services will significantly strengthen its worldwide leadership as t...Read more
Merus appoints Mark Iwicki as President of the Supervisory Board -
Utrecht, The Netherlands, June 1, 2015 -- Merus B.V., a leader in developing ...Read more
Rudy Dekeyser and Clemens van Blitterswijk join LSP - [ NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA ]
Amsterdam, February ...Read more
Iris Sample Processing, a division of IRIS International and KREATECH Diagnostics sign distribution agreement for novel automated FISH sample preparation in Europe and North America - Amsterdam, March 1, 2012
Iris Sample Processing, a division of IRIS Internati...Read more
TEAM
Martijn Kleijwegt founded LSP in 1998 and is currently a Managing Partner...Read more
Mark Wegter joined LSP in 1998 and is currently a Managing Partner and co-own...Read more
Dr René Kuijten joined LSP in 2001 and is Managing Partner and co-own...Read more
Joachim (JR) Rothe, PhD, joined LSP in 2002 and is a Managing Partner and...Read more
John de Koning, PhD, joined LSP in 2006 and is a Partner of the firm. His pri...Read more
Geraldine O’Keeffe joined LSP in 2008. She became a Partner of the firm in ...Read more
Fouad Azzam, PhD, MBA, joined LSP in 2007. He became a Partner of the firm in...Read more
Jörg Neermann, PhD, joined LSP in 2007 as Partner. Jörg’s prime focus a...Read more
Anne Portwich, PhD, has been with LSP since 2001. She is a Partner in LSP’s...Read more
Rudy Dekeyser, PhD, joined LSP in 2012 and became Managing Partner of LSP’s...Read more
Professor Clemens van Blitterswijk, PhD, joined LSP in 2012. He became a Part...Read more
Drew Burdon, PhD, MBA, joined LSP in 2019 as an Investment Manager. Drew’s ...Read more
Bruno Holthof is the Chief Executive Officer (CEO) of Oxford University Hospi...Read more
Vincent Brichard, MD, PhD, MBA, joined LSP in 2016 as a Venture Partner. He w...Read more
Felice Verduyn-van Weegen joined LSP in 2015 as Associate and became an I...Read more
Edwin van den Broek joined LSP in December 2015 as a senior equity trader and...Read more
Karin Kleinhans, PhD joined LSP in 2015 as Associate and became an Investment...Read more
Arno de Wilde joined LSP in 2019 as an analyst. He is part of the LSP investm...Read more
Anna Bellmunt, PhD, joined LSP as an Analyst in 2020. She is part of the LSP ...Read more
Isabel Bahm, PhD, joined LSP in 2018 as Analyst. Isabel provides in-depth ana...Read more
Sonia Hallen, PhD, joined LSP in 2019. She is part of the LSP investment team...Read more
Hans Clevers MD PhD, has been a Venture Partner with LSP since 2001, except d...Read more
Pauline Bieringa is the Chairman of the NYSE Euronext listed LSP Life Science...Read more
Professor Dr. Anton Pijpers DVM PhD is the Chairman of the Supervisory Board/...Read more
André Olijslager is the Chairman of the Advisory Committee of the LSP Health...Read more
Maarten Scholten is the Chairman of the Supervisory Board of LSP Advisory. Un...Read more
Douwe Breimer PhD has been the former Chairman of the Supervisory Board of LS...Read more
Merijn Klaassen RC CAIA FRM joined LSP in early 2008 as Chief Financial Offic...Read more
Koen Sintnicolaas joined LSP in 2016 as a Business Controller. Within LSP he ...Read more
Bas Vaessen joined LSP as General Counsel in 2008. His prime focus and respon...Read more
Erika Boot joined LSP as Legal Counsel in 2009. With a background in civil an...Read more
Gisela Wolf joined LSP as Legal and Compliance Manager in 2018. Her prime...Read more
Edie de Kwaasteniet joined LSP as Tax Counsel in 2019. Within LSP she is resp...Read more
Hannie Wiersema joined LSP at our Amsterdam office in February 2006 as financ...Read more
Suzanne Dwinger is office manager and personal assistant at LSP within the Am...Read more
Manuela Jaeger joined LSP in October 2019 as an office manager and executive ...Read more
Follow us
